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Adult skeletal muscle possesses a remarkable regenerative ability, which largely depends 
on satellite cells; however, in severe muscular dystrophies, such as Duchenne muscular 
dystrophy (DMD), skeletal muscle integrity is compromised and the muscle is often replaced by 
a mixture of fibrous tissue and white adipocytes in a process termed fibro-adipogenic 
degeneration. The precise cellular origin and the environmental cues responsible for 
accumulation of fat/fibrotic tissues during the course of the disease remain unknown. Using a 
previously published preplate technique, two distinct populations of muscle derived cells from 
skeletal muscle were isolated: 1) a rapidly adhering cell population (RACs), which is non-
myogenic, Pax7- and expresses the mesenchymal stem cell (MSC) marker PDGFRα, hence 
termed non-myogenic MSCs (nmMSCs); and 2) a slowly adhering cell population (SACs) which 
is Pax7+ and highly myogenic, termed myogenic progenitor cells (MPCs). In this dissertation, the 
role of nmMSCs in the histopathogenesis of dystrophin/utrophin double knock out (dKO) mice, 
an animal model of DMD, was investigated. The nmMSCs become activated during the disease 
progression in dKO mice, displaying increased proliferation and adipogenic, osteogenic, and 
fibrogenic potentials compared to age-matched WT counterparts. The activated dKO-nmMSCs 
also significantly reduced the myogenic potential of the dKO-MPCs, an effect, at least partially, 
mediated by the secreted frizzled-related protein 1 (sFRP1) released by the dKO-nmMSCs. 
These results suggest that nmMSCs are likely the cell source involved in the deposition of non-
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muscle tissues in dKO muscles and activation of nmMSCs likely exacerbates muscle wasting 
and degeneration during the disease progression by limiting the myogenic potential of MPCs.  
Interestingly, the nmMSCs also appear to play an important role in muscle regeneration after 
acute injury in normal WT muscle. The nmMSCs isolated from cardiotoxin injured WT muscle 
significantly enhanced the myogenic potential of MPCs after co-cultivation, suggesting that the 
nmMSCs may facilitate muscle repair in normal WT muscle. These results suggest that the 
muscle micro-environment plays a major role in the fate of nMMSCs. Overall, data from this 
dissertation proposes that a therapeutic strategy targeting nmMSCs could represent a novel 
treatment for DMD.   
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1.0  INTRODUCTION 
1.1 DUCHENNE MUSCULAR DYSTROPHY 
Muscular dystrophy (MD) describes a heterogeneous group of approximately 40 inherited 
disorders characterized by progressive muscle weakness, degeneration, and wasting. Duchenne 
muscular dystrophy (DMD) is one of the most common childhood muscular dystrophies, with an 
incidence rate of approximately one in every 3,500 live male births (1). It is an X-linked, genetic 
disease caused by frameshift mutations in the dystrophin gene, which results in complete absence 
of functional dystrophin protein, a relatively large, 472 kilo-Dalton (kD) cytoskeletal protein in 
both skeletal and cardiac muscle tissues (2-4). Dystrophin, along with other dystrophin-
associated proteins (DAPs), stabilize the muscle cell membrane, both physically and 
physiologically. The major role of dystrophin is to link cytoskeletal F-actin to the dystrophin 
associated glycoprotein (DAG), which binds to laminin-2 in the overlying basal lamina of the 
extracellular matrix (5, 6). In dystrophic muscle, this linkage is disrupted and muscle fibers are 
damaged during muscle contraction. This process results in an efflux of soluble muscle-specific 
enzymes, such as creatine kinase (CK),  an influx of calcium ions, and the recruitment of T cells, 
macrophages, and mast cells to the damaged muscle, causing progressive myofiber necrosis (7, 
8). The damaged fibers degenerate and the muscle progenitor cells are recruited to regenerate 
new muscle fibers, but this regeneration is inefficient due to repeated cycles of necrosis over 
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time, which eventually leads to an exhaustion/depletion of the satellite cell population (9). 
Continuous weakness and degeneration of striated muscle eventually result in kyphosis and 
scoliosis of the spine (90%-95% of patients), a loss of independent ambulation by the middle of 
the patient’s second decade,  and a fatal outcome due to cardiac or respiratory failure by the third 
decade (6, 10, 11). Interestingly, although the typical histological pattern of 
degeneration/regeneration of muscle fibers in most skeletal muscle groups and elevated CK 
concentration in serum are present in affected boys long before the clinical onset of the disease, 
DMD patients usually exhibit no obvious clinical manifestation until the age of 3 to 5 years (11).  
Still no effective treatments are available for DMD patients, and currently corticosteroids, 
including glucocorticoids, prednisone, and deflazacort, are used to delay the disease progression; 
however, the mechanism of action of corticosteroids in DMD is not completely understood (6, 
12, 13). One possible explanation is that glucocorticoids bind directly to inflammatory cell 
receptors, enhancing the transcription of anti-inflammatory genes or inhibiting pro-inflammatory 
factors, such as NF-κB (14). A few studies have shown that prednisolone may increase 
dystrophin-related protein expression in muscle cell cultures of mdx mouse, an animal model of 
DMD (14, 15). Although there are beneficial effects of medical management of patients with 
corticosteroids, including increased muscle strength, prolonged walking, delayed decline of 
pulmonary function, and delayed wheelchair use by up to 4-5 years, there are some major side 
effects (6, 16, 17). The most frequent side effects of corticosteroids include weight gain, growth 
retardation, personality changes, and reduced bone density with potential osteoporosis (6, 18). 
Moreover, as of January 2015, only prednisone is available in the US.  
Current research studies on treatment regimens for DMD have centered on the restoration 
of dystrophin; however, these technologies alone have faced limitations. Over the last decade, 
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many different gene therapy strategies for DMD, including plasmid transfer, exon skipping, and 
viral- or non-viral-mediated therapy has been focusing on delivering a dystrophin gene to the 
dysfunctional muscle tissue and has entered clinical trials. However, the extensive size of the 
dystrophin gene and the long-term expression of gene construct into skeletal muscle have limited 
clinical applicability (19). Besides, Adeno-associated virus injection to deliver sarcoglycans 
reported to cause an immune reaction against the viral proteins in dystrophic dogs (20). 
In addition, one of the most striking pathological conditions in advanced cases of DMD is 
an accumulation of intramuscular fibro-fatty tissues or calcium deposits, with the muscle being 
almost entirely replaced by non-muscle tissues (6, 21, 22). At an early age, only mild pathology 
is observed due to sufficient regeneration and repair medicated by muscle stem cells; however, 
when the stem cell pool is eventually depleted, the functional skeletal muscle is replaced by a 
mix of fibrous tissue and white adipocytes in a process termed pseudohypertrophy and fatty 
degeneration (Fig. 1).  
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Figure 1. Histopathology of gastrocnemius muscle (GAS) from a patient who died of 
pseudohypertrophic muscular dystrophy, Duchenne type. 
 
Hematoxylin-eosin staining of muscle from a patient with DMD. Cross section of this patient’s 
muscle shows extensive replacement of muscle fibers by adipose cells. In addition, variation in 
muscle fiber size, central nuclei, and areas of fibrosis are observed. (Image adapted from 
http://phil.cdc.gov/phil/home.asp, Edwin P. Ewing Jr., 1972). 
 
 
In DMD, the accumulation of intramuscular fat and/or fibrotic tissue represents the 
hallmarks of advanced stage disease and the presence of these non-muscle tissues significantly 
affects muscle structure, function, and recovery (6). First of all, severe intramuscular adipose 
tissue development may induce deregulation of muscle homeostasis, which associates with 
potential insulin resistance (23, 24). Secondly, adipocytes/fatty infiltration/adipose tissue 
exacerbate the muscle wasting process in DMD patients, compromise muscle function, and alter 
the tissue environment, severely limiting the success of muscle regeneration (6, 20, 23). 
Therefore, the use of dystrophin replacement alone to treat the primary defect in DMD patients 
may not be successful for rescuing muscle from progressive degeneration and wasting, especially 
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at the later stages of the disease (20, 25). Current therapies have not found a solution to block or 
replace formation of ectopic non-muscle tissues in the DMD skeletal muscle, and unfortunately, 
the precise origin of ectopic adipocytes or fibrotic tissue in dystrophic muscle is not clearly 
understood. More studies on mechanisms regulating the calcification and fibro-fatty 
degeneration in skeletal muscle of DMD must be performed to improve currently available 
treatment methods.  
 
1.2 FAT TISSUE DEPOSITION IN SKELETAL MUSCLE 
Although adult skeletal muscle has great regenerative potential, some experimental and 
pathological conditions lead to impaired regeneration with adipose tissue deposition. Ectopic 
adipocyte deposition in the skeletal muscle characterizes various disorders, including muscular 
dystrophy (26, 27), inflammatory myopathies (28), scarcopenia due to disuse or aging (29-31), 
obesity and  type-2 diabetes (32). The muscle fat includes both acellular lipid droplets within the 
fibers, and interstitial adipocytes (33, 34). These intramuscular fat tissue in skeletal muscle is 
usually white, although brown adipocytes have also been identified, and are characterized by 
drops of triglycerides and cholesterol ester, which can be identified by Oil-Red O staining and 
the expressions of peroxisome proliferator-activated receptor γ2 (PPARγ2), perilipin, leptin, 
adiponection and fatty acid-binding protein 4 (FAP4) (34, 35). 
In DMD, intramuscular fat can reach as much as 46% of muscle mass in young boys and 
older boys can show even higher muscle fatty infiltration, as measured by magnetic resonance 
imaging (MRI) (36, 37). The gluteus maximus had the most frequent and greatest degree of fatty 
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infiltration (36), but adipose tissue deposition was also observed in semi-membranous muscles, 
biceps, and rectus femoris, with the least amount found in gracilis and sartorius muscles (36-39). 
Interestingly, it has been shown that muscles showing clear signs of inflammation and edema 
were not necessarily correlated to fatty infiltration. In fact, some muscles were infiltrated by fat 
tissue without apparent inflammatory reactions (39, 40). 
To investigate accumulation of fat tissue in the skeletal muscle, the glycerol-induced fatty 
degenerating murine model can be used (24); however, ectopic fat deposition has been detected 
after cardiotoxin induced or freeze injuries as well as rotator cuff injuries (41, 42). The cell 
population responsible for the development of the adipose tissues in those animal models is still 
unclear. It has been shown that satellite cells, non-myogenic PDGFRα+ cells, pericytes or muscle 
fibroblasts are all capable of forming intramuscular fat in skeletal muscle under a variety of 
pathological conditions (43-46). Fatty infiltration is irreversible and progressive if left 
untreated. Given the negative impact of ectopic adipocytes and these conflicting reports about 
the original cell source responsible for the phenotype, more studies are needed to understand the 
cellular and molecular players of fat deposition and accumulation in skeletal muscle.   
   
1.3 IN VIVO MODELS FOR DMD 
Several animal models are available for use in DMD research, including canine and murine 
models. These mammalian models for DMD are important to understand the underlying cellular 
and molecular mechanisms of DMD as well as to test therapeutic approaches to alleviate the 
muscle weakness in DMD (47).   
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1.3.1 Canine Model 
The canine model of DMD (cxmd), including the dystrophic Golden Retriever (GRMD) and the 
Beagle (CXMDj) dogs, displays spontaneous mutations of the dystrophin gene, resulting in X-
linked muscular dystrophy. They result from a point mutation at the 3’ consensus splice site of 
intron 6 of the dystrophin gene, which leads to skipping of exon 7, a disruption in the open 
reading frame, and premature termination of translation (47). Of those, GRMD dogs show the 
most similar pathogenesis to that of human patients with DMD, suffering from a rapidly 
progressing and fatal muscle wasting and degeneration, fat accumulation, fibrosis, and a 
shortened life span (47-49). In GRMD, the incomplete muscle repair starts at age of 6-9 weeks, 
and further results in progressive weakness and gait abnormalities by 6 months. The GRMD 
dogs become less active at about 9 months of age and the severely affected dogs show 
difficulties rising and walking only a few steps. They also develop kyphosis by the age of 6 
months (47). The canine model has been mostly used for research focusing on myoblast transfer, 
gene transfer, and oligonucleotide therapy. Although the GRMD model is highly relevant for 
DMD research, dogs are not considered as an ideal laboratory animal. One important drawback 
of cxmd is the high degree of variability in the severity of disease between breeds and among 
littermates as well as the high cost associated with maintaining a dystrophic dog colony (48, 50).  
1.3.2 Murine Model 
Research on DMD has benefited from the availability of mdx mice, in which a point mutation on 
exon 23 of the mouse dystrophin gene introduces a premature stop codon, eliminating expression 
of full length dystrophin protein (11, 48, 50). During the first 6 weeks of life, mdx mice show 
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histological signs of muscular dystrophy; however, the subsequent course of their disease is 
markedly milder compared to that seen in DMD (5, 47, 51). The mdx mice show milder 
weakness, pseudohypertrophy, kyphosis, and have nearly normal life span. Also, the mdx mice 
do not develop the severe myofibrosis, fatty infiltration, and cardiomyopathy characteristic of 
end-stage DMD (5, 52) until they become around 24 months old (Fig. 2). These differences have 
limited the value of mdx mice as a model for investigating the accurate pathogenesis of DMD 
and testing potential interventions. It is also important to understand why the dystrophin 
deficiency is less deleterious to mice than to humans as the information could help in finding 
therapies for DMD or other muscle diseases. One possible explanation for the difference between 
mdx mice and DMD patients is that utrophin, a homologous protein of dystrophin, compensates 
for the lack of dystrophin more effectively in mdx mice than in DMD patients (51). 
The fact that the occurrence of later stage manifestations, including ectopic adipose and 
fibrotic tissue accumulation and calcium deposits in skeletal muscle, are rare in mdx mice have 
lead researchers to use the glycerol-induced fatty degenerating mice model to investigate 
histopathogenesis of various skeletal muscle diseases. A routine protocol of 25µl of 50% 
glycerol intramuscular injection in mouse TA muscles is shown to induce myofiber damage by 
plasma membrane disruption, followed by some areas of muscle regeneration accompanied by 
apparent fat deposition between muscle fibers (24). However, these animals still possess pitfalls. 
It is difficult to fully investigate the degenerative-regenerative events occurring during the 
progression of disease when using the intramuscular glycerol injection model in a normal, wild 
type (WT) or mdx mouse. The skeletal muscle repair and regeneration processes involve the 
cascade of many different cells types, cytoskeletal elements, chemoattractant molecules, and 
immune cells (10, 53). Therefore, one time injection of glycerol to induce fatty degeneration 
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cannot fully recapitulate the cellular and molecular events that occur in the progressive 
pseudohypertroph in DMD. Moreover, the degree of adipose tissue formation in chemically 
induced skeletal muscles is dependent on the genetic background of mice (42, 54) .    
In order to overcome challenges with mdx mice, Grady et al. developed the 
dystrophin/utrophin double-knock out (dystrophin-/-, utrophin-/-, dKO) mice (5). The dKO mouse 
shows numerous clinically-relevant manifestations, including muscle wasting, crippling, 
kyphosis, heart failure, degenerative musculoskeletal abnormalities and other life-threatening 
phenotypes (51, 55). The normal life span of dKO mice is usually 8-10 weeks, and by that stage, 
dKO mice develop advanced sarcopenia and pseudohypertrophy (51, 55, 56) and the dystrophic 
phenotype demonstrated by dKO mice closely mimics DMD pathophysiology. Therefore, the 
dKO mouse is regarded as a better model for therapeutic trials to determine the effectiveness of 
various treatment modalities. As shown in Figure 2, skeletal muscles of 6-8 week old dKO mice 
exhibit severe muscle histopathology and muscular dystrophy compared to that of an age-
matched mdx mouse (Fig. 2). Immunohistochemistry staining of 6-8 week old dKO 
gastrocnemius muscle (GAS) tissue section shows rigorous muscle damage, necrotic muscle 
fibers, and accumulation of calcium deposits, fibrotic tissue and lipids. However, the cellular 
origin and the environmental cues responsible for these changes in the skeletal muscles of DMD 
or dKO mice remain unknown. For these reasons, studies done in this dissertation will be 
focusing on utilizing dKO mice to investigate the major cell source responsible for formation of 
non-muscle tissues in dystrophic skeletal muscle during the disease progression. 
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Figure 2. Comparison of mdx and dKO skeletal muscle histopathology. 
Gastrocnemius muscles (GAS) from 6-8 week old mdx and dKO mice was compared. Muscle 
histopathology and muscular dystrophy were more severe in the dKO mice compared to the age-
matched mdx mice. H&E staining shows severe muscle damage in the GAS of dKO mice. Larger 
necrotic areas in the GAS of dKO mice were identified with mouse IgG staining. Alizarin Red 
staining visualized calcium deposits in 8 week old dKO-GAS. Trichrome staining identified 
larger fibrotic regions in dKO-GAS. AdipoRed staining identified more lipids accumulation in 
dKO-GAS. Image adapted from (A. Lu et al. 2014). 
 
 
1.4 SKELETAL MUSCLE STEM/PROGENITOR CELLS: MDSCS AND RACS 
From the time of their initial description in 1961, satellite cells (SCs), located underneath the 
basal lamina of the muscle fiber, are responsible for the maintenance and regeneration of the 
adult skeletal muscle (57). SCs are considered to be mitotically quiescent; however, upon 
activation, they will migrate, rapidly undergo extensive proliferation, differentiate into myoblasts, 
and finally fuse with existing muscle fibers to form new multinucleated myofibers. Cell surface 
markers  associated with SCs include M-cadherin, Sca-1, CD34, and Pax3 and Pax7 transcription 
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factors, which are known to play essential roles in the early specification, migration, and 
myogenic differentiation (58-60) (Fig. 3). During population expansion, quiescent SCs undergo 
asymmetric division to produce myoblast, while a portion retains “stemness” in order to 
repopulate the stem cell niche (57, 61). Therefore, SCs are often referred to as muscle stem cells 
which can regenerate skeletal muscle and display self-renewal properties; however, they are 
mainly committed to myogenic lineage (62). Myoblasts, so-called activated SCs, loose 
expression of Pax7 and begin to express myogenic regulatory factors (MRFs) including Myf5, 
MyoD, and myogenin (Fig. 3) (63, 64). They have been extensively studied as candidates for cell 
therapy for treating muscular dystrophies and other skeletal muscle disorders (65-68).  
Other cell populations with myogenic or without myogenic potential, including PICs 
(PW1+ interstitial cells), pericytes, side population cells, muscle derived stem cells, myogenic 
endothelial cells, Fibro/adipogenic Progenitors (FAPs), and PDGFRα+ cells, have been isolated 
from skeletal muscle utilizing a variety of methods, including cell culture selection techniques, 
flow cytometry-based sorting, and Hoechst dye exclusion (Table 1) (44, 69-73). Our research 
group has reported the isolation of muscle resident stem/progenitor cells using the modified 
preplate technique (74). As shown in Figure 3, the preplating process consists of serial plating of 
muscle derived cells to separate them according to their adhesion properties to type I Collagen 
(74-76). The most rapidly adhering cell (RAC) fractions consist of cells that adhere during the 
early stages of the preplate technique, within minutes to two hours of seeding. RACs are known 
to be comprised of a mixture of fibroblast-like and mesenchymal progenitor cells that are highly 
positive for Sca-1, which is expressed by progenitor populations of multiple tissues, and CD34, 
which is expressed by muscle stem cells (73, 77). Although RACs are partially able to regenerate 
muscle in vivo, higher regeneration potential is exhibited mostly by the slowly adhering cell 
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(SAC) fractions, which consist of cells obtained by successive re-plating of non-adherent cells 
for 6 days (78).  Previously in our lab, we have characterized murine SACs as “muscle derived 
stem cells” (MDSCs) since they exhibit the stem cell characteristics of self-renewal and multi-
lineage differentiation (75, 79). SACs also express both stem (Sca-1, CD34), myogenic (desmin, 
MyoD), and endothelial (CD31, CD144) cell surface markers, distinguishing them from SCs (74, 
77).  
 
 
 
Figure 3. Schematic isolation of mouse muscle derived cell populations via modified  
preplate technique. 
 
The mouse skeletal muscle biopsy was first enzymatically digested, and then, cells were 
preplated on collagen I coated flasks. After separation of cells by adherence rates, two main 
populations were acquired, rapidly-adhering cells, RACs, and slowly-adhering cells, SACs. 
RACs express Sca-1 and CD34, and SACs express Sca-1, CD34, CD31, CD144, and desmin 
(Gharaibeh et al. 2008 and Jankowski et al. 2001). SACs were found to contain a population of 
stem and progenitor cells and were named as muscle derived stem cells, MDSCs.  
 
 13 
1.4.1 Muscle derived stem cells (MDSCs) and muscle regeneration 
The MDSCs are characterized by slow cycling, long term self-renewing cells, as they can divide 
for more than 30 passages in proliferation medium with an average division time of 15.1 hours 
(74). It was previously reported that when compared to committed muscle precursor cells 
(myoblast), the MDSCs demonstrated a higher intramuscular engraftment capability in both 
skeletal and cardiac muscles (75, 80). In addition to healing skeletal muscle damage, MDSCs are 
also shown to aid in the repair of bone and cartilage defects, and improve heart function in 
murine models of acute myocardial infarction (81-83). The exact mechanism involved in the 
improved regenerative potential of the MDSCs remains unclear; however, current evidence from 
animal studies suggests that their high survival property due to elevated resistance to stress is 
critical (84-86) as well as their release of soluble factors such as vascular endothelial growth 
factor (VEGF) (83, 87).  Our previous studies suggest that improved regenerative capacity of 
MDSCs is linked to their increased level of antioxidants, including glutathione and superoxide 
dismutase (84, 85) and elevated aldehyde dehydrogenase level, which endowed MDSCs with 
enhanced stress resistance capability post cell transplantation (86). In addition, soluble factors, 
such as VEGF have been found to promote MDSCs mediated tissue repair (83, 87).  
In addition to murine MDSCs, systemic delivery of allogeneic wild type canine SACs to 
immunosuppressed dystrophic dogs has been reported to significantly improve dystrophic 
phenotype. Donor SACs have been shown to contribute to myofiber regeneration, SCs 
replenishment, and long-term dystrophin expression, which consequently improve muscle 
weakness in the dystrophic dog (88). Furthermore, evidence already exists that SACs isolated 
from humans also have the potential for skeletal and cardiac muscle regeneration (78, 89). SACs 
are currently undergoing clinical trials for the treatment of urinary incontinence and ischemic 
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heart failure (90). Therefore, MDSCs could provide an attractive therapeutic avenue for muscle 
diseases.  
1.4.2 Rapidly adhering cells (RACs) and muscle regeneration 
Rapidly adhering cells (RACs) have been shown by our group to be comprised of mostly 
fibroblastic-like cells that are highly positive for Sca-1 and CD34, but are negative for muscle 
progenitor cell markers, including Pax7, desmin and MyoD (74, 77). Another study on human 
RACs further indicated that they are also highly positive for CD44, CD73, CD90, and CD105 
(78), cell surface markers known to be expressed by mesenchymal stem cells (MSCs) (91). 
However, few studies have been done to characterize RACs or investigate their role in muscle 
regeneration/degeneration under muscle injury or pathological conditions (74, 77, 78).   
Recently, several investigations suggest that muscle resident Sca-1+/CD34+ cells, isolated 
using fluorescence activated cell sorting (FACS), play an important role in maintaining muscle 
homeostasis by interacting with SCs (44, 73, 92, 93). These Sca-1+/CD34+ cells are referred as 
Fibro/Adipogenic Progenitors (FAPs) since they have the dual potential to differentiate into both 
adipocytes and fibroblasts in vitro and in vivo. Although FAPs do not arise from the myogenic 
lineage, nor directly participate in forming myotubes/myofibers, they have been shown to 
facilitate muscle regeneration after injury (92).  Muscle damage results in rapid recruitment of 
eosinophils, which secrete IL-4/IL-13 immune signals. The activation of IL-4/IL-13 signaling 
further promotes proliferation of FAPs to support myogenesis while inhibiting their 
differentiation into adipocytes (92).  Another in vitro co-culture experiment shows that signals 
originating from FAPs generate a transient pro-myogenic differentiation niche for myoblast or 
SCs (73). A recent study suggests that follistatin secreted by FAPs might contribute to FAPs 
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ability to promote SC myogenic activity (93). Moreover, it has been reported that FAPs can also 
mediate the ability of histone deacetylase (HDAC) inhibitors to promote satellite cell-based 
regeneration in mdx mice (93).  
Interestingly, FAPs are also known to be highly positive for platelet derived growth 
factor receptor α (PDGFRα), a well-known marker for muscle resident mesenchymal stem cells 
(44). It has been reported that, of the muscle-derived cell populations, only FAPs or PDGFRα+ 
mesenchymal progenitor cells display efficient in vitro and in vivo adipogenic/fibrogenic 
differentiation potentials and can participate in ectopic adipocyte formation when transplanted 
into glycerol induced fatty degenerating muscle or mdx mouse (44, 73, 94). However, others 
report inconsistent results and show that SCs,  muscle fibroblasts, or pericytes are also all 
capable of forming intramuscular fat and fibrotic tissue in a variety of pathological conditions 
(45, 46, 95, 96). Furthermore, the cellular origin responsible for the formation of non-muscle 
tissues in severe dystrophic mouse model, such as dKO mouse remains unexplored. It appears to 
be that the RACs are also expressing high levels of Sca-1 and CD34, two cell surface markers 
expressed by FAPs, and therefore, it will be important to examine whether RACs can contribute 
to dystrophic muscle histopathology or influence myogenic activity of muscle progenitor cells 
(MPCs) of dKO mice.  
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Population Cell markers Location Differentiation 
In vitro 
Differentiation 
In vivo 
Reference 
Satellite cells Pax7, CD34, 
Myf5, 
VCAM-1 
Between the 
basal lamina 
and 
sarcolemma 
Myogenic, 
adipogenic, 
osteogenic, 
fibrogenic? 
myogenic (51, 95, 
97) 
MDSCs Sca-1, CD34, 
CD31, 
CD144, 
PW1? 
Muscle 
interstitium 
Myogenic, 
Adipogenic, 
Osteogenic, 
Chondrogenic, 
haematopoietic 
Myogenic, 
osteogenic, 
chondrogenic, 
fibrogenic 
(98-102) 
PICs PW1, Sca-1 
CD34,  
Muscle 
interstitium 
Myogenic myogenic (70, 103) 
IAP PW1, Sca-1, 
PDGFRα 
Muscle 
interstitium 
Adipogenic  Adipogenic (103) 
Pericytes AP, 
PDGFRβ, 
NG2 
endothelium Myogenic, 
adipogenic, 
osteogenic, 
fibrogenic 
Myogenic, 
adipogenic 
(45, 69, 
96, 104, 
105) 
RACs Sca-1, CD34,  Muscle 
interstitium 
Adipogenic? 
osteogenic?  
chondrogenic? 
fibrogenic? 
Adipogenic? 
osteogenic? 
fibrogenic? 
(74, 77) 
FAPs Sca-1, CD34 Muscle 
interstitium 
Adipogenic, 
fibrogenic 
Adipogenic, 
fibrogenic 
(73) 
PDGFRα+ 
cells 
PDGFRα, 
Tie2 
Muscle 
interstitium 
Adipogenic, 
osteogenic, 
chondrogenic, 
fibrogenic 
Adipogenic, 
fibrogenic  
(44, 94, 
106) 
Fibroblasts Tcf4, 
Vimentin 
Muscle 
interstitium 
Adipogenic, 
fibrogenic 
Adipogenic, 
fibrogenic 
(107, 108) 
Side 
population 
cells 
Hoechst-
negative 
Muscle 
interstitium 
Myogenic, 
adipogenic, 
fibrogenic, 
osteogenic, 
haematopoietic 
Myogenic (67, 109, 
110) 
 
Table 1. Summary of a different population of skeletal muscle-resident progenitors. 
 
MDSCs, muscle derived stem cells; PICs, PW1+/Pax7- interstitial cells; IAP, interstitial 
adipogenic progenitors; RACs, rapidly adhering cells; FAPs, fibro/adipogenic progenitors; 
PDGFRα/β, platelet derived growth factor receptor α/β; Tcf4, transcription factor 7-like 2.  
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1.5  EFFECT OF MUSCLE MICROENVIRONMENT ON STEM CELL FUNCTION 
Stem cells exhibit two key characteristics, which are the ability to both self-renew and 
differentiate into specialized, mature cell types (111). These two properties endow stem cells 
with great promise for cell replacement therapy in regenerative medicine. Therefore, 
understanding the mechanisms underlying stem cell maintenance and differentiation are central 
to increase the efficacy of stem cell use in therapeutic applications.  
The phenotypic characterization and function of stem cells are controlled by both 
intrinsic and extrinsic mechanisms (112). During past years, studies have tried to identify 
intrinsic regulatory mechanisms shared by all self-renewing cells by examining tissue-specific 
stem cells; however, gene expression profiling from these studies showed inconclusive results 
and have not been yet able to define a common set of genes responsible for stem cell behavior 
(113-115). This finding has led to a shift in research focus from investigating intrinsic regulatory 
mechanisms to studying the extrinsic micro environmental factors. The extrinsic regulation of 
stem cells is largely dependent on the local multi-cellular microenvironment, also known as the 
“stem cell niche”, which includes growth factors, cytokines, matrix-mediated signals, and cell-
cell interactions (112, 116, 117). For example, in tumor-bearing hosts, stem cells might be 
affected within their niches by the tumor microenvironment (TME), which consists of many 
different cell types, including cancer cells, immune cells, fibroblasts, and myofibroblasts, as well 
as the surrounding extracellular matrix. Several studies have shown that the TME can disrupt 
localization, stability, self-renewal, and differentiation potentials of normal adult stem cells, 
including bone-marrow derived MSCs and hematopoietic stem cells (HSCs), by altering 
signaling pathways and gene-expression profiles in these cell types (118-120).  
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 The process of aging also contributes to stem cell niche dysfunction. Aging is evident in 
most tissues and organ system, and studies done on cellular and molecular changes in aged 
muscle have suggested that the aged niche can also disrupt proliferation and function of muscle 
stem cells, including SCs and Pax7+ MPCs (121, 122). For example, Brack and colleagues 
reported that aged-muscle microenvironment induces Wnt signaling, alters SC fate from 
myogenic to fibrogenic fate and increases fibrosis in skeletal muscle (121).  The authors further 
demonstrated that such myogenic-to-fibrogenic transition is influenced by the systemic 
environment, suggesting that stem cell functionality conversion is reversible, at least to some 
extent. When they exposed the old tissue to a youthful systemic environment, by establishing 
parabiotic pairings of old animals to young animals (heterochronic pairings), they were able to 
reduce the collagen deposition in regenerating areas of muscles of aged mice compared to 
isochronic pairings (parabiotic parings of old animals to old animals) (121). More recent 
investigation further suggests that aged-muscle niche also increases fibroblast growth factor 
(FGF) signaling, which leads to an initial loss of quiescence followed by a depletion of the 
muscle stem cell pool (122). These changes in aged-muscle, can explain at least in part, the 
declined regenerative potential of skeletal muscle with age.  
Other studies also report that the muscle microenvironment dictates stem cell survival 
and differentiation potentials. For example, Jackson et al. reported that mesenchymal progenitor 
cells isolated from traumatized human skeletal muscle exhibited stronger adipogenic 
differentiation potentials compared to osteogenic or chondrogenic potentials, suggesting that 
muscle injury may cause alteration in these cells activity (123). Additionally, another study 
showed that survival and differentiation of FAPs were modulated by the environment of the 
recipient tissue as FAPs engrafted and formed adipocytes only when they were transplanted into 
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muscles injected with glycerol to induce fatty degeneration. In healthy, normal muscles, FAPs do 
not survive or engraft post transplantation (73). Our previous studies also demonstrated that the 
release of local environmental stimuli after skeletal muscle injury alters the differentiation 
potential of MPCs, including MDSCs, into fibrotic cells (102).  All of these studies illustrate the 
importance of signals from the local microenvironment within the skeletal muscle on 
determining the function and fate of stem cells.  
The effects of the muscle microenvironment on stem cell function have also been 
examined in the context of chronic muscle disease, such as DMD. It is now well established that 
many of the pathological phenotypes of DMD are not only caused by the lack of dystrophin, but 
are also due to the complex interactions of muscle resident stem/progenitor cells with the 
surrounding microenvironment (56, 95, 124). For example, adipocytes accumulated in DMD 
skeletal muscle may influence the skeletal muscle microenvironment by secreting various 
cytokines and by modifying the basal lamina (24). These changes in muscle milieu will impact 
stem cell function to delay repair and regeneration, but enhance inflammation, which exacerbates 
the disease condition. Recently, Biressi and colleagues observed that SCs isolated from mdx 
muscles have compromised myogenic potentials. These SCs were less myogenic and more 
fibrogenic and showed elevated expression of fibrogenic genes rather than myogenic genes.  
Another study done by Saccone and colleagues also demonstrated that the dystrophic 
muscle environment causes changes in FAPs plasticity only in a young mdx mouse, which is a 
mild dystrophic animal model. The study shows that FAPs isolated from HDAC inhibitor (TSA) 
treated young mdx mice behave differently from their wild type (WT) controls and could form 
myosin heavy chain–positive myotubes (125). The authors suggest that HDAC inhibition induces 
two core components of the myogenic transcriptional machinery, MyoD and BAF60C, which 
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ultimately directs pro-myogenic differentiation at the expense of fibro/adipogenic differentiation. 
Under normal conditions, such as WT mice that were not exposed to TSA, FAPs are known to 
lack myogenic potential and thus do not directly contribute to regenerating myofibers. 
Importantly, the beneficial effect of HDAC inhibitors on myogenic potential of FAPs was 
completely lost in old mdx mice, which exhibit significantly more severe dystrophic features, 
including fat accumulation and fibrosis, compared to young mdx mice. Thus, FAPs isolated from 
TSA treated old mdx mice were unable to adopt a myogenic gene expression program at all 
(125).  
As normal tissue stem/progenitor cells are ultimately responsible for tissue regeneration 
and repair following targeted cell- or gene-based therapies in most tissue types, including 
skeletal muscle, understanding how normal muscle stem/progenitor cells are influenced by 
dystrophic microenvironments is of great importance. Our recent studies also revealed the 
complexities of the dKO muscle microenvironment, including chronic inflammation, fibrosis, 
heterotrophic ossification, fatty infiltration as well as elevated FGF expressions compared to age-
matched WT controls or mdx mice (24, 56), which lead us to postulate that these changes in local 
milieu may have significant impacts on determining fate of stem/progenitor cells in dKO 
muscles. Therefore, in this dissertation, we will investigate how changes in muscle micro-milieu 
regulate proliferation and differentiation as well as the activity of stem/progenitor cells in dKO 
mice.  
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1.6 WNT SIGNALING IN SKELETAL MUSCLE  
The formation of skeletal muscle is tightly regulated process that is modulated by several 
different signaling pathways including wingless-type mouse mammary tumor virus integration 
site family (Wnt) signaling (126). Wnt is a secreted protein that is essential during embryonic 
muscle development and in the maintenance of skeletal muscle homeostasis in the adult (127-
129). Skeletal muscles, except for some craniofacial and esophageal muscles, are derived from 
somites, segmented structures that form pair-wise along the anterior and posterior axis of the 
developing embryo, during embryonic development (130, 131). In embryonic stage, Wnt 
signaling is necessary to specify early somites into myogenic lineage and initiate the myogenesis. 
Within the embryonic MPCs, Wnt regulates expressions of Pax3, Pax7, MyoD, and Myf5, also 
known as myogenic regulatory factors (MRFs), key transcription factors for myogenic lineage 
progression (126, 132, 133). In adult skeletal muscle, both canonical and non-canonical Wnt 
signals are required for regulating SC differentiation and mediate the self-renewal of SCs and the 
growth of muscle fibers (127, 129).  
1.6.1 Wnt Signaling during adult muscle regeneration 
Skeletal muscle is regenerated by muscle progenitor cells. After muscle injury, satellite cells 
actively proliferate and differentiate into myoblasts. Afterward, they fuse together or with 
regenerating myofibers to repair skeletal muscle (57). The molecular events determining each 
step are still unclear; however, numerous investigations suggest that Wnt signaling molecules are 
involved in governing self-renewal and differentiation of SCs (126, 127, 134).  
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The canonical Wnt signals (Fig. 4) are mediated by Frizzled (Fzd) receptors and their 
low-density lipoprotein receptor-related protein (LRP) co-receptors. In the absence of Wnt 
molecules, constitutively synthesized cytosolic β-catenin induces the formation of degradation 
complex with two tumor suppressor proteins; adenomatous polyposis coli (APC) and Axin, 
which acts as scaffolds to capture newly synthesized β-catenin. This complex mediates 
phosphorylation of β-catenin by glycogen synthase kinase 3 (GSK3) and active kinase casein 
kinase-1 (Ck1) molecules. In the presence of Wnt ligand, Dishevelled (Dsh) is activated to 
recruit Axin-APC complex to LRP and this will disassemble the β-catenin degradation complex. 
As a result, β-catenin (lacking phosphorylation) is accumulated in the cytosol and is imported 
into the nucleus. In the nucleus β-catenin binds to T-cell transcription factor/lymphoid enhance 
factor (Tcf/Lef) upon replacement of the transcriptional Groucho repressors to activate Wnt 
target genes (126, 135). Several secreted antagonists control Wnt signaling activity. The non-
canonical Wnt signals do not require the transcriptional activity of β-catenin and are mostly 
transduced through Fzd receptors without involvement of LRPs. Stimulation of Wnt could be 
through Fzd, other small G proteins, or JNK. By contrast to canonical Wnt, non-canonical Wnt 
signaling pathways are not well characterized and understood (126). Secreted Frizzled-related 
proteins (sFRP1, 2, 4, and 5), Frzb and Wnt inhibitory factor (Wif) can bind Wnt directly and 
prevent it from activating their receptors (135). Additionally, there are other Wnt antagonists that 
bind to the LRP co-receptors include Dickkopf 1 (Dkk1) (136) and Wise (137). 
In skeletal muscle, Wnt5a, Wnt5b, Wnt7a, and Wnt4 are expressed. Early stages of 
muscle regeneration are linked to upregulation of Wnt5a, Wnt5b, and Wnt7a and downregulation 
of Wnt4 expressions whereas later stages after injury are characterized with increased Wnt7b and 
Wnt3a expressions (129). Several studies indicated that non-canonical Wnt signaling stimulated 
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by Wnt7a and Fzd7, is essential for self-renewal of SCs (127, 129). It has been reported that 
Wnt7a-deficient mice exhibit significantly reduced numbers of SCs following regeneration, 
supporting the idea that non-canonical Wnt is involved with SC proliferation (138). On the other 
hand, the differentiation of SCs and myoblasts are controlled mostly through canonical Wnt 
signaling. Several in vitro studies involving inhibitors of GSK3β or pharmacological activators 
of canonical Wnt signaling strongly supports a role for canonical Wnt signaling in facilitating the 
differentiation of SCs and myoblasts (127, 139). Moreover, exogenous induction of canonical 
Wnt signaling with Wnt3a during the early stage of muscle regeneration resulted in premature 
differentiation of SCs and eventually led to depletion of the stem cell pool (126).  All of the 
above supports that Wnt molecules play critical roles in different aspects of muscle development 
and regeneration. 
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Figure 4. Overview of the canonical Wnt signaling cascades. 
In canonical Wnt signaling pathway, Wnt binds to Frizzled (Fzds) receptors and their low-
density lipoprotein receptor related protein 5 or 6 (LRP5/6). This will further activate 
dishelleved, (Dsh) to recruit β-catenin degradation complex, which consists of adenomatous 
polyposis coli (APC), Axin, case in kinase I (CK1) and glycogen synthase kinase-3 (GSK-3). 
These events free the β-catenin from degradation complex and leads to an accumulation of 
stabilized β-catenin (lacking phosphorylation) in the cytosol, resulting in nuclear translocation. 
In the nucleus, β-catenin complexes with TCF/LEF (T-cell factor/lymphoid enhancer factor) 
transcription factors and acts as a transcriptional co-activator to induce context-dependent 
Wnt/β-catenin target genes. In the absence of Wnt molecules, constitutively synthesized 
cyotosolic β-catenin forms degradation complex with APC, CK1, Axin, and GSK-3. This 
complex mediates phosphorylation of β-catenin by CK1, which further primes β-catenin and 
GSK-3 for proteasome-mediated degradation. (Image adapted from de Lau et al. 2012)  
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1.6.2 Wnt signaling during aging and disease 
Wnts are well-known signaling molecules that are active in muscle tissue during development 
and regeneration; however, they are also involved in the build-up of connective tissue in the 
muscles of aged mice (121). The regenerative potential of skeletal muscle declines with age and 
is usually associated with increased fibrous connective tissue and adipose tissue. Interestingly, 
Brack and colleagues linked enhanced canonical Wnt signaling by circulating Wnt molecules or 
Wnt-like factors, to decreased myogenic potential of SCs with age (121). Moreover, numerous 
studies suggest that dysregulation of Wnt co-receptors or Wnt inhibitors occurs in multiple 
diseases, including cancer, osteoporosis, obesity, and cardiovascular diseases (140-142). For 
example, secreted frizzled related protein 1 (sFRP1), an endogenous modulator of Wnt/β-catenin 
signaling, participates in the paracrine regulation of human adipogenesis. It has been reported 
that constitutive ectopic expression of sFRP1 results in extensive adipose tissue expansion during 
the early stages of high fat diet (HFD) – induced obesity (140). Additionally, dysregulation of 
Wnt inhibitory factor 1 (Wif1) in bone marrow niche has reported to be associated with 
exhaustion of Hematopoietic stem cells (HSCs) (141).  
It has been shown that Wnt signaling is elevated in dystrophic mdx muscle (95); however, 
the mechanism behind this Wnt signaling elevation is still unknown. Also unknown is whether 
Wnt is upregulated in dKO mice, a more severe dystrophic mouse model than a mdx mouse. 
Further studies are necessary to investigate if Wnt is also elevated in dKO mice and whether 
increased Wnt may induce any changes in function of stem/progenitor cells, including not only 
MPCs but also non-myogenic stem/progenitor cells in dKO mice. 
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1.6.3 Wnt signaling in adipogenesis 
Wnt protein has an important function, not only in myogenesis, but also in adipogenesis. In 
general, Wnt signaling negatively regulates adipogenesis and favors myogenesis (143) and its 
effect on directing myogenic vs adipogenic potentials in myoblasts had been well investigated 
(144-146). Although myoblasts are highly committed cells for skeletal muscle regeneration, 
these cells are reported to exhibit plasticity in developmental potential and can be differentiated 
into myogenic, adipogenic, or osteogenic lineages (144). Numerous investigations demonstrated 
that the canonical Wnt-β-catenin pathway, likely mediated by Wnt10, has an important role in 
the control of intramuscular adipose tissue expansion as well as adipogenic potential of different 
cell types, including myoblasts (144-146). For instance, myoblasts from Wnt10b deficient mice 
were transdifferentiated into C/EBPα and PPAR-γ2 expressing adipocytes, suggesting that 
disruption in Wnt signaling may contribute to impaired myoblast regenerative capacity and to 
increased fat deposition in skeletal muscle (144). Additionally, these studies showed that 
deficiency or inhibition of Wnt10 is involved in adipose tissue deposition in skeletal muscle after 
cardiotoxin injury and rotator cuff tear (144, 146). These results indicated that Wnt is one of the 
important molecular regulators in fatty infiltration in skeletal muscle. Therefore, examining Wnt 
signaling in dKO mice will help the understanding of the mechanism behind the accumulation of 
adipose tissue in dystrophic muscles.  
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2.0  ISOLATION AND CHARACTERIZATION OF MULTIPOTENT, NON-
MYOGENIC MESENCHYNMAL STEM CELLS RESIDING IN SKELETAL MUSCLE 
2.1 INTRODUCTION 
Figures 5, 6&8 of Chapter 2 are adapted from a published article in Human Molecular Genetics: 
Jihee Sohn1, Aiping Lu1, Ying Tang1, Bing Wang1, and Johnny Huard1,2*. (2015) Activation 
of non-myogenic mesenchymal stem cells during the disease progression in dystrophic 
dystrophin/utrophin knockout mice. Hum Mol Gen In press. 
1Stem Cell Research Center, Department of Orthopaedic Surgery, University of Pittsburgh, 
School of Medicine 
2Department of Microbiology and Molecular Genetics, University of Pittsburgh School of 
Medicine 
 
Mesenchymal stem cell (MSC) therapy offers the possibility of a renewable source of 
replacement cells and tissues to treat various types of diseases (147, 148). MSCs are especially 
considered a strong candidate for clinical use in injury healing because they are believed to be 
responsible for tissue growth, wound healing, and replacing cells during normal tissue 
homeostasis (149-153). Since their first identification in 1974 by Friedenstein and colleagues, 
MSCs, also called mesenchymal stromal cells, are characterized as a subset of fibroblast-like, 
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non-hematopoietic adult stem cells that originate from the mesoderm (154-156). MSCs are 
readily grown in culture and maintain pluripotency after prolonged culture and under appropriate 
stimulus, they can differentiate into cells of the mesodermal lineages, including bone, fat, and 
cartilage cells both in vitro and in vivo (91, 155).  Interestingly, recently reported studies suggest 
that MSCs are able to differentiate into non-mesenchymal cell lineages as well, such as 
tenocytes, skeletal myocytes, and neurons (157, 158). Moreover, numerous preclinical studies 
suggested that MSCs are effective in treating both mesenchymal and non-mesenchymal lineage 
derived tissues, myocardial infarction, cornea damage, brain, spinal cord, lung injuries and in 
immune disorders, including systemic lupus erythematosus (SLE), amyotrophic lateral sclerosis, 
and Crohn’s disease (147, 149, 151, 152, 159, 160). Greater research interest has developed in 
MSCs because they are free of both ethical concerns, can be use autologously, easy to collect, 
express trophic factors, and have immunomodulatory effects (161, 162).   
MSCs are present in many different tissues of young and adult individuals, including 
adipose tissue, bone marrow, umbilical cord, lung, amniotic fluid, and even peripheral blood 
(147). Recently, PDGFRα+ mesenchymal progenitors, Tie2+ progenitors and Sca-1+/CD34+ 
fibro/adipogenic progenitors (FAPs) have been identified as skeletal muscle resident 
mesenchymal lineage cells, utilizing fluorescence activated cell sorting (FACS) (44, 73, 106, 
163). Platelet derived growth factor receptor α (PDGFR α) with stem cell antigen 1 (Sca-1) are 
known to be expressed by a population of cells isolated from mouse bone marrow, that are 
highly enriched for MSCs (164, 165). Interestingly, PDGFRα+ cells and FAPs seem to show 
discrepancy in their phenotypic features since PDGFRα+ cells can undergo adipogenic, 
osteogenic, and chondrogenic differentiation whereas FAPs fail to give rise to mineralized bone, 
or cartilage under in vitro induction (44, 73).  
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Our research group has isolated various populations of muscle derived cells from skeletal 
muscle of mice based on their adhesion properties to type I collagen-coated flasks through 
utilizing a preplate technique, a marker profile-independent method (74). The most rapidly 
adhering cell fraction, (RAC) or preplate 1-2 (PP1-2) can be collected within 2-24 hours of 
isolation. The PP3-5 cells adhere within 5 days of plating and are composed of satellite cells and 
myoblasts. They have been shown to be mainly committed to the myogenic lineage and readily 
fuse to form myotubes (56). Finally, slowly adhering cell fraction (SACs) or PP6 can be 
collected 6 days after isolation. SACs have been characterized as muscle derived stem cells 
(MDSCs), which are capable of undergoing multilineage differentiation with a strong myogenic 
potential and self-renewing ability (98-100). MDSCs are superior when compared to myoblasts 
for muscle regeneration and repair (75). RACs, have been shown to be comprised of mostly 
fibroblastic-like cells with no myogenic potential; however, they have never been thoroughly 
characterized (74).  
In this study, we isolated the PP1, or RACs that are attached to the flask within two hours 
of preplating and characterized them as non-myogenic mesenchymal stem cells (nmMSCs) with 
adipogenic, osteogenic, and chondrogenic differentiation potentials. The nmMSCs express 
PDGFRα and Sca-1 proteins, but lack desmin or Pax7 expressions and has no myogenic 
potential. Further immunostaining of muscle cryosections indicated that the nmMSCs were 
located at the muscle interstitium, which separates them physically from satellite cells (SCs), 
which are located underneath the basal lamina. Results shown here indicated that preplate 
technique successfully enabled us to isolate a population of multipotent, non-myogenic MSCs 
from skeletal muscle independent of cell surface marker profiles.  
 
 30 
2.2 MATERIALS AND METHODS 
Animals: C57BL/10J (wild type; WT) mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). Mice ranged in age from 3 to 8 weeks. Specific ages for each experiment are 
described below. All animal protocols used for these experiments were approved by the 
University of Pittsburgh’s Institutional Animal Care and Use Committee. 
Cell isolation and culture: Primary non-myogenic mesenchymal stem cells (nmMSCs) 
and muscle derived stem cells (MDSCs) were isolated from 3 - 8 week old WT mice using a 
modified preplate method previously described (56, 74, 166). Briefly, following enzymatic 
digestion of skeletal muscle tissue, muscle derived cells were re-plated on collagen type I 
(C9791, Sigma-Aldrich) coated flasks over a period of days. Two hours after isolation, a rapidly 
adhering cell population was collected and characterized as nmMSCs. Six days after preplating, 
a slowly adhering cell population was obtained, which has been described to contain the MDSC 
fraction of cells (75). The nmMSCs and MDSCs were cultured in proliferation medium (PM) 
containing 10% fetal bovine serum, 10% horse serum, 0.5% chick embryo extract and 1% 
Penicillin-Streptomycin in Dulbecco’s modified Eagle’s medium (DMEM, 11995-073, 
Invitrogen). 
Immunophenotyping: Flow cytometry was performed on nmMSCs and MDSCs. One-
hundred thousand WT-nmMSCs and WT-MDSCs were collected, washed with PBS containing 
2% FBS, centrifuged, and then placed on ice. The cells were then re-suspended in a 1:10 dilution 
of mouse serum (M5905, Sigma-Aldrich) in PBS and incubated for 10 minutes. PE-conjugated 
rat anti-PDGFRα (12140181, eBioscience) and FITC-conjugated rat anti-CD34 (553733, BD) 
were added to each tube (1µl/100,000 cells) and incubated for 30 minutes on ice. Only one 
antibody was used in each tube. The cells were then rinsed in 300µl of cold washing buffer (2% 
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FBS in PBS, 4 degrees). A single color antibody was used to optimize fluorescence 
compensation settings for multicolor analyses.  
mRNA analysis was performed via reverse transcriptase polymerase chain reaction 
(RT-PCR): Total RNA was obtained from nmMSCs and MDSCs isolated from 6-8 week old 
WT animals using Trizol reagent (Invitrogen) and a RNeasy Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. Reverse transcription was performed using a 
Maxima first strand cDNA synthesis kit (Fermentas) according to the manufacturer’s protocol. 
PCR reactions were performed using an iCycler Thermal Cycler (Bio-Rad) as previously 
described (24) and PCR products were separated by electrophoresis with 1% agarose gels. The 
primers used for PCR are listed in Table 1. Each set of oligonucleotides were designed to span 
two different exons to avoid background amplification of genomic DNA. The data was 
quantified by densitometry using Adobe Photoshop 7.0. 
Gene Forward primer Reverse primer Location 
desmin AACCTGATAGACGACCTGCAG GCTTGGACATGTCCATCTCCA 615-873 
Pax7 GTGCCCTCAGTGAGTTCGAT CCACATCTGAGCCCTCATCC 499-667 
Sca-1 CCTACTGTGTGCAGAAAGAGC CAGGAAGTCTTCACGTTGACC 89-331 
PDGFRα GACGAGTGTCCTTCGCCAAAGTG CAAAATCCGACCAAGCACGAGG 1658-1976 
β-actin CCACACCCGCCACCAGTTCG TACAGCCCGGGGAGCATCGT 234-772 
Table 2. Primer sequences used in Chapter 2. 
Immunofluorescence staining: Muscle cryosections or cells were fixed with 4% 
paraformaldehyde for 10 minutes and blocked with 10% donkey serum plus 0.1% Triton X-100 
for 1 hour at room temperature. Slides or cells were then incubated with goat anti PDGFRα 
(1:100, R&D) or chicken anti-mouse laminin (1:500, Abcam) in 5% donkey serum. Next, 
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sections were incubated with secondary antibodies including Alexa488-conjugated anti-goat IgG 
(1:300, Invitrogen) or Alexa594-conjugated anti-chicken IgG (1:300, Invitrogen) in PBS for 45 
minutes. WT-nmMSCs and WT-MDSCs were fixed and permeabilized with 10% formalin plus 
0.1% Triton X-100 for 10 minutes at room temperature and rinsed 2 times with PBS. Cells were 
stained for Pax7 or desmin using a mouse monoclonal anti-Pax7 antibody (1:150, DSHB, Iowa 
city, Iowa) and mouse monoclonal anti-desmin antibody (1:100, Sigma) with a mouse-on-mouse 
(M.O.M) staining kit (Vector Labs, Burlingame, CA), according to manufacturer’s directions.  
Differentiation Assays  
Adipogenic differentiation assay: A total of 35,000 nmMSCs were cultured in 24-well collagen 
type I-coated plates for 21 days in adipogenic differentiation medium (PT-3004, Lonza). When 
the cells reached 100% confluence, three cycles of induction/maintenance medium were applied 
to the cells to induce optimal adipogenic differentiation. Each cycle consisted of incubating the 
nmMSCs with supplemented adipogenic induction medium and cultured for 2-3 days, followed 
by 2-3 days of culture in supplemented adipogenic maintenance medium. At the end of the third 
cycle, the cells were incubated in adipogenic maintenance medium for an additional 5-7 days. 
Adipogenesis was assessed using Oil Red O (O0625, Sigma-Aldrich) to stain for intracellular 
lipid accumulation. For adipocyte differentiation quantification, cells were stained with 
AdipoRed (NC9049267, 30µl/ml, Fisher) and DAPI, and fluorescence intensities were analyzed 
with a spectrophotometer. The AdipoRed fluorescence emission readings were normalized to the 
total number of cells in each well.  
Osteogenic differentiation assays: A total of 35,000 nmMSCs were cultured in osteogenic 
medium which contained DMEM, 10% FBS, supplemented with dexamethasone (D2915, 
0.1µM, Sigma-Aldrich), ascorbic-acid-2-phosphate (A8960, 50µg/ml, Sigma-Aldrich), 10mM β-
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glycerophosphate (G6251, Sigma-Aldrich), and BMP2 (M11306AAB, 100ng/ml, Medtronic). 
Osteogenesis was assessed using a Fast Blue Alkaline Phosphatase (ALP) kit (041M4338, 
Sigma) and by staining mineralized matrix with alizarin red. ALP activity was quantified with an 
ELISA-based assay according to the manufacturer’s protocol (123).  
Chondrogenic differentiation assays: A micromass culture technique was used as described by 
Kishimoto and colleagues (167). One-hundred thousand cells were incubated for a week in 
chondrogenic induction medium (PT3003, Lonza) supplemented with 100ng/ml BMP2 and 
20ng/ml TGFβ3 (PHG9305, Invitrogen). Micromass cultured cells were fixed with 10% formalin 
and stained with 1% alcian blue (pH 1.0) for 30 min. For quantification, 250,000 cells were 
cultured in pellets for 4 weeks in chondrogenic induction media. Sulphated glycosaminoglycans 
(GAGs) production was quantified using a Blyscan assay kit (Biocolor, Carrickfergus) according 
to the manufacturer’s protocol.  
Myogenic differentiation: 30,000 cells were plated on 24-well plates in DMEM supplemented 
with 2% FBS (Fusion medium, FM) to stimulate myotube formation. Three days after 
differentiation, the cells were fixed with 10% formalin for 8 min and bright field images were 
taken.   
Statistical analysis: Data from ≥ 4 samples from each subject were pooled for statistical 
analysis. Results are given as means ± SD. Statistical significance of any difference was 
calculated using Student’s t test. Values of p < 0.05 were considered statistically significant.  
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2.3 RESULTS 
Isolation of rapidly adhering cells (RACs) utilizing preplate technique. 
Utilizing the preplate technique, rapidly adhering cells (RACs) were obtained within 2 
hours of isolation, which is similar to the isolation method utilized to collect bone marrow 
derived mesenchymal stem cells (BM-MSCs) (168), and muscle derived stem cells (MDSCs) 
were obtained 6 days after isolation (Fig. 5). RACs were isolated from skeletal muscles of 3-6 
week old wild type (WT) mice and characterized by examining their cell surface markers and 
stem cell behaviors. After 3-4 passages, the RAC population (Fig. 5B) had a very similar 
morphology to that of BM-MSCs (Fig. 5A), which is substantially different from the MDSCs 
that are small, spherical and refractive under phase contrast microscopy (Fig. 5C).  
 
 
Figure 5. Morphology of rapidly adhering cells (RACs) isolated from skeletal muscle. 
Phase contrast microscopy images of (A) bone marrow derived mesenchymal stem cells (MSCs), 
(B) RACs, and (C) muscle derived stem cells (MDSCs) isolated from 3-6 week old WT mice. 
Scale bar = 50µm.  
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RACs and MDSCs are expressing different markers. 
 
Next, we performed RT-PCR, flow cytometry of PDGFRα and CD34, and 
immunostaining for muscle progenitor cell markers (MPCs), Pax7 and desmin, to identify 
progenitor lineages from dissociated skeletal muscle. RT-PCR analysis (Fig. 6A) and 
quantification (Fig. 6B) of the relative gene expression levels in the MDSCs and RACs showed 
that the MDSCs expressed significantly higher levels of Pax7 and desmin, while the RACs 
expressed significantly higher levels of Sca-1, which is expressed by progenitor populations of 
multiple tissues (73), and PDGFRα, a well-known marker of mesenchymal stem cells (MSC) 
(44). Further flow cytometry analysis of PDGFRα indicated that more than 99% of the MDSCs 
were PDGFRα negative (Fig. 6C) while nearly 99% of the RACs were PDGFRα positive. We 
next examined the expression of desmin and PDGFRα protein by immunostaining and observed 
that the RACs expressed PDGFRα while the MDSCs expressed desmin (Fig. 6D&F). Lastly, 
immunostaining for Pax7 showed that nuclear-localized Pax7 expression was only observed in 
MDSCs and not in the RACs (Fig. 6E&F). Therefore, upon myogenic induction, only MDSCs 
were able to differentiate into myotubes (Fig. 6E). These results suggested that preplate 
technique enabled us to prospectively isolate myogenic progenitors (MDSCs) and non-myogenic 
progenitor cells (RACs) from skeletal muscle.  
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Figure 6. Phenotypic characterization of the WT- RACs and the WT-MDSCs. 
 
(A) RT-PCR analysis of lineage markers desmin, Pax7, Sca-1, and PDGFRα of freshly isolated 
WT-MDSCs and WT-RACs. (B) Quantification of desmin, Pax7, Sca-1, and PDGFRα 
expression levels by the WT-RACs and the WT-MDSCs. (C) Fluorescence activated cell sorting 
(FACS) plots show that the RACs are CD34 and PDGFRα positive cells while the MDSCs are 
PDGFRα negative cells. (D) Immunostaining for desmin and PDGFRα were performed. scale 
bar = 25µm (E) Immunostaining for Pax7 indicated that the WT-RACs are Pax7 negative and are 
unable to differentiate into myotubes, while WT-MDSCs are Pax7 positive and are highly 
myogenic, scale bar = 50µm. (F) Quantification of immunostaining of desmin, PDGFRα, and 
Pax7. (n=3). Error bars indicate ‘mean ± SD’. * p <0.05.  
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Anatomic localization of RACs in skeletal muscle. 
 Next, we examined the anatomical localization of the RACs in the skeletal muscle. We 
performed immunostaining for PDGFRα, Pax7, and laminin in gastrocnemius muscle (GAS) 
cryosections from 4 week old WT mice (Fig. 7). PDGFRα+ RACs were localized at the 
interstitial space of muscle tissue, (Fig. 7C-E) whereas Pax7+ cells, most likely satellite cells, 
were located beneath the basement membrane as indicated by laminin staining (Fig 7A, B, and 
E). These localizations suggest that PDGFRα+ cells and Pax7+ muscle progenitor cells represent 
discrete cell populations.  
 
 
 
Figure 7. Localization of PDGFRα+ cells in adult skeletal muscle. 
(A-E) Gastrocnemius muscle sections were stained with antibodies against Pax7, PDGFRα, and 
laminin (A); Pax7 (B); Pax7 and Dapi (C); PDGFRα (D); PDGFRα and Dapi (E); Pax7, 
PDGFRα, Dapi, and laminin. PDGFRα+ cells were located at the interstitial space of muscle 
tissue while Pax7+ cells were localized under the basal lamina. Scale bar = 25µm   
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Multilineage differentiation potentials of WT-RACs. 
The biological property that most uniquely identifies MSCs is their capacity for trilineage 
mesenchymal differentiation (91). We confirmed that under appropriate induction conditions, the 
WT-RACs exhibited evidence of osteogenic, adipogenic, and chondrogenic differentiation 
potentials (Fig. 3). The WT-RACs upregulated their surface expression of alkaline phosphatase 
(ALP) and began to generate a mineralized deposits, which was visualized with Alizarin Red 
staining, under osteogenic conditions (Fig. 3A). Under adipogenic conditions, WT-RACs also 
accumulated intracellular lipid, which was visualized with AdipoRed staining (Fig. 3B). 
Furthermore, WT-RACs began to express sulphated glycosaminoglycans (GAGs), which were 
visualized with alcian blue staining, under chondrogenic conditions (Fig. 3C). Based on the 
RAC’s marker expression and their trilineage differentiation capacities (Fig. 2&3), we referred 
to the RACs as non-myogenic mesenchymal stem cells (nmMSCs).  
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Figure 8. Trilineage differentiation potentials of the WT-RACs. 
The WT-RACs were able to undergo (A) osteogenic (Alizarin Red staining for mineralization) 
(B) adipogenic (AdipoRed staining for lipid accumulated in the cells) and (C) chondrogenic 
differentiation (Alcian blue staining for glycosaminoglycans and chondroitin sulfate (Cs)) (n>4). 
Error bars indicate ‘mean ± SD’. * p <0.05. Scale bar = 50µm. 
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2.4 DISCUSSION 
Mesenchymal stem cells (MSCs) are adult stem cells traditionally found in the bone marrow, but 
they can be harvested from a variety of adult tissues. Here we isolated the non-myogenic MSCs 
from mouse skeletal muscle and examined their marker profiles and differentiation potentials. 
Cells were obtained after two hours of isolation using previously published modified preplate 
technique and further analyzed for their cell surface marker expressions. Although RACs were 
previously considered as fibroblast-like cells, our data from this study suggest that RACs are 
strongly positive for the expressions of Sca-1 and PDGFRα, mesenchymal stem cell surface 
markers. Further differentiation assays confirmed that RACs can undergo adipogenesis, 
osteogenesis, and chondrogenesis, but fail to undergo myogenesis as they lack Pax7 and desmin 
expression. Based on their marker expression and trilineage differentiation potentials, we termed 
RACs as non-myogenic mesenchymal stem cells (nmMSCs). 
Other groups also have reported MSCs isolated from skeletal muscle using FACS, a 
method used to isolate and purify cells on the basis of cell surface markers. Sca-1, PDGFRα, 
and/or CD34 are reported to be highly expressed by muscle resident MSCs (44, 73, 163, 169); 
however, isolating stem cells based on the cell surface marker has some limitations. First, the 
degree of marker expressions may change during cell expansion and under different cell culture 
conditions. For example, it has been reported that positive or negative CD34 expression on 
MSCs is controversial and likely a consequence of cell culturing (170-172). The CD34 antigen, a 
transmembrane cell surface glycoprotein, has been reported as a hematopoietic stem cell (HSC) 
marker (173), and only recently, has a population of CD34+ cells been found in mouse skeletal 
muscle (77, 169). In the past, The Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy stated the minimal criteria for identifying MSCs is 
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lack of CD34 expression (91); however, more recently, it has been suggested that lack of CD34 
expression is not reliable since the expression of CD34 is a potential culture-inducing 
phenomena (170). In fact, some studies have reported persistent CD34 expression in cultured 
murine MSCs, although they were initially sorted as CD34- population (174, 175). In contrast, 
other studies indicated that CD34 protein is either gradually downregulated or modified to a form 
that is nonreactive to CD34 antibodies during cell culture (176-178).   
Another possible problem with FACS isolated stem cell is that defined cell markers for 
MSCs may not be exclusive to MSCs but are shared with other populations. For instance, Sca-1 
is known to be expressed by stem/progenitor cells of many different tissues and is expressed by 
SCs as well as MDSCs (77). Furthermore, CD70, CD90, and CD105 antigens have been used to 
identify MSCs; however, these three markers are co-expressed in a wide variety of cells, 
including fibroblasts, chondrocytes, and hematopoietic progenitor cells, neurons, and endothelial 
cells (171, 179). Therefore, even when used in combination, they are certainly incapable of 
identifying MSCs.   
Characterization of the nmMSCs indicated that we have isolated two heterogeneous, but 
highly purified, functionally different cell populations, nmMSCs and MDSCs, residing in the 
skeletal muscle. It has been reported that MDSCs are Pax7+ multipotent, muscle progenitor cells 
(MPCs) with high myogenic regeneration potentials both in vitro and in vivo (74, 75, 80). We 
confirmed that the nmMSCs are 100% Pax7- cells that are unable to fuse, and therefore, the 
nmMSCs are unlikely to contain MDSCs. Moreover, since the MDSCs are Pax7 positive and 
highly myogenic in nature (myotube formation) and are PDGFRα negative (>99%), it is unlikely 
that MDSCs contain nmMSCs.  
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As we already mentioned, other studies also have reported the presence of non-myogenic 
cell populations in skeletal muscles of mouse and human that exhibit mesenchymal lineage 
differentiation or regeneration potentials. These cell populations include PDGFRα+ 
mesenchymal progenitors (44, 163), fibro/adipogenic progenitors (FAPs), and mesenchymal 
progenitor cells (123). These cells possess abilities to become adipocytes, osteoblasts, and 
chondrocytes, but fail to form myotubes. Our results indicate that the cell surface marker 
expression, multipotency, and the anatomical location of the nmMSCs are very similar to that of 
these cells reported by others. Although Joe and colleagues initially reported that FAPs do not 
differentiate into osteogenic cells in vitro (73), studies done by Goldhamer and colleagues 
demonstrated that FAPs also possess osteo-/chondrogenic potentials in vivo (106). Osteogenic 
potential of FAPs were probably underestimated since osteogenesis performed by Joe and 
colleagues was only assessed in vitro without bone morphogenic protein (BMP) in induction 
medium. Taken together, our data suggest that preplate technique is highly efficient in isolating 
stem/progenitor cells from skeletal muscle.  
More interestingly, mesenchymal progenitor cells isolated from traumatized human 
muscle tissue were reported to be multipotent, although somewhat limited compared to bone 
marrow derived MSCs (BM-MSCs), and exhibit trophic properties of stem cells, including 
immunoregulatory and pro-angiogenic effects (123). These studies, including ours, suggest that 
previously recognized muscle fibroblasts may represent multipotent MSCs, which can be used as 
a substitute for BM-MSCs for regenerative medicine therapies. One important area that remains 
unclear is whether these nmMSCs maintain their multi-lineage potentials in vivo. Therefore, 
future studies focusing on examining the in vivo characteristics and behavior of nmMSCs will be 
necessary.  
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In conclusion, the preplate technique was utilized to isolate rapidly adhering cells that are 
strongly positive for PDGFRα and Sca-1 and exhibit multipotency in vitro. These cells have no 
ability to undergo myogenic differentiation and therefore are named non-myogenic mesenchymal 
stem cells (nmMSCs). Lacking myogenic potential restricts nmMSCs’ utility for muscle 
regeneration and repair; however, their capacity for adipocyte, osteocyte, and chondrocyte 
differentiation suggest that they might be a useful cell source for tissue repair especially bone 
and articular cartilage regeneration and repair.  
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3.0  ACTIVATION OF NON-MYOGENIC MESENCHYMAL STEM CELLS DURING 
THE DISEASE PROGRESSION IN DYSTROPHIC DYSTROPHIN/UTROPHIN 
KNOCKOUT MICE 
3.1 INTRODUCTION 
Chapter 3 is adapted from a published article in Human Molecular Genetics: 
Jihee Sohn1, Aiping Lu1, Ying Tang1, Bing Wang1, and Johnny Huard1,2*. (2015) Activation 
of non-myogenic mesenchymal stem cells during the disease progression in dystrophic 
dystrophin/utrophin knockout mice. Hum Mol Gen In press. 
1Stem Cell Research Center, Department of Orthopaedic Surgery, University of Pittsburgh, 
School of Medicine 
2Department of Microbiology and Molecular Genetics, University of Pittsburgh School of 
Medicine 
 
Adult skeletal muscle possesses a remarkable regenerative ability dependent on muscle 
progenitor cells such as satellite cells which reside beneath the basal lamina, closely juxtaposed 
to the muscle fibers (57, 180, 181). Despite the presence of these muscle regenerative cell 
populations, skeletal muscle integrity can be debilitated by the deposition of adipose and fibrotic 
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tissues in a variety of pathological conditions including Duchenne muscular dystrophy (DMD) 
(21, 22).  
DMD is one of the most common childhood muscular dystrophy, with an incidence of 
approximately one in every 3,500 live male births (182). It is an X-linked, inherited disease 
caused by a lack of functional dystrophin, an essential transmembrane muscle protein within the 
dystrophin-glycoprotein complex in both skeletal and cardiac muscle cells (2, 3). In dystrophic 
muscle, the damaged fibers degenerate, undergo necrosis, and lose their ability to regenerate 
during the progression of the disease. Satellite cells are recruited to regenerate new myofibers, 
but this regeneration is often inefficient due to repeated cycles of degeneration and regeneration, 
which eventually leads to an exhaustion/depletion of the satellite cell population (9). Progressive 
muscle weakness and degeneration usually leads to the loss of independent ambulation by the 
middle of the patient’s second decade and a fatal outcome due to cardiac or respiratory failure by 
their third decade of life (10, 11).  
Recent evidence has emerged implicating adult stem cell dysfunction in the progression 
of histopathology in DMD. These studies have reported that the rapid progression of muscle 
weakness in DMD might correlate with the decline in the number of functional muscle 
progenitor cells (MPCs) (56, 124, 183). Of note, despite the lack of dystrophin from birth, the 
onset of the muscle weakness typically does not occur until patients reach 4-8 years of age, 
which happens to coincide with the exhaustion/depletion of the MPC pool due to the repeated 
cycles of degeneration and regeneration that the muscle fibers undergo (9, 183).  
One of the most striking pathological conditions in advanced cases of DMD is the 
accumulation of adipocytes, calcium deposits, and fibrosis. Importantly, even with the 
occurrence of MPC depletion, we observed the formation of more adipose and fibrotic tissue in 
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the skeletal muscle, heart, and diaphragm of 6-8 week old dKO mice compared to age-matched 
mdx mice (24, 56). However, it remains unclear what cell population is responsible for the 
formation of these non-skeletal muscle tissues. Of note, although the mdx mouse is commonly 
used as an animal model of DMD, 6-8 week old mdx mice exhibit only a mild dystrophic 
phenotype (muscle fiber degeneration and necrosis) and do not develop the severe 
histopathologies exhibited by age matched dKO mice, such as the accumulation of calcium 
deposits and fibrosis (56). Therefore, we focused this study on examining a population of cell 
potentially responsible for the formation of the above dystrophic histopathology.  
Our research group has isolated two distinct populations of muscle derived cells from the 
skeletal muscle of dKO mice utilizing a previously published preplate technique (74); 1) a 
rapidly adhering cell (RAC) fraction, and 2) a slowly adhering cell (SAC) fraction. In previous 
publications, we characterized the SACs as a heterogeneous population of Pax7+ cells called 
muscle-derived stem cells (MDSCs), which are muscle progenitor cells (MPCs) with high 
myogenic potentials, both in vitro and in vivo (74, 75, 79). We recently reported that MPCs 
isolated from 6-8 week old dKO mice display a significant reduction in their proliferation 
capacity, resistance to oxidative stress, and multilineage differentiation potentials, when 
compared to MPCs isolated from age-matched mdx and WT mice. These results suggest that in 
contrast to mdx and WT mice, rapid stem cell depletion occurs in the dKO mice (56). We 
therefore postulated that the decline in MPCs may be responsible for the progressive reduction in 
muscle regeneration and the rapid occurrence of the histopathology observed in the dKO mice 
(56). Since MPCs become impaired during the progression of the disease, it is unlikely that these 
cells are involved in the formation of ectopic non-muscle tissues. In the previous chapter, we 
characterized RACs as non-myogenic mesenchymal stem cells (nmMSCs) that are highly 
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positive for PDGFRα, Sca-1 and CD34 (77), cell surface markers that are also expressed by 
fibro/adipogenic progenitors (FAPs) (73); however, their role in skeletal muscle has not been 
thoroughly investigated. Therefore, we hypothesized that the RACs might be responsible for the 
deposition of fibrotic tissue, ectopic bone and fat observed in dystrophic mice.  
In this study, we show that the rapid accumulation of lipids, calcium deposits, and 
fibrosis correlate with the progression of the disease in dKO mice. We determined that the 
proliferation and adipogenic/osteogenic potentials of nmMSCs isolated from 1, 4, and 6-8 week 
old dKO mice were progressively activated as the disease progresses, suggesting that the 
activation of nmMSCs is closely associated with the deposition of non-muscle tissues in the dKO 
mice. In addition, 6-8 week old dKO-nmMSCs displayed significantly enhanced proliferation 
potentials, in vitro and in vivo, as was their adipogenic, osteogenic, and fibrogenic differentiation 
capacities, in comparison to age-matched WT-nmMSCs. Our co-cultivation study further 
suggests that the activated dKO-nmMSCs exert a negative effect on dKO-MDSCs by inhibiting 
their myogenic potential (reduced ability to form myotubes). Results shown here indicate that 
activation of nmMSCs is not only closely associated with the rapid occurrence of fibrosis, 
ectopic calcification and fat accumulation, but may also contribute to continuous muscle 
degeneration and weakness in the dystrophic dKO mice.  
3.2 MATERIALS AND METHODS 
Animals: C57BL/10J (wild type; WT) mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). Dystrophin/utrophin knockout (dKO) mice, originally characterized by Deconinck 
and colleagues (51), were generated by crossing heterozygous dystrophin-/-; utrophin+/- mice 
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(55, 184). Genotyping was performed by polymerase chain reaction (PCR) analysis of tail 
samples. Mice ranged in age from 5 days to 8 weeks. Specific ages for each experiment are 
described below. All animal protocols used for these experiments were approved by the 
University of Pittsburgh’s Institutional Animal Care and Use Committee. 
Cell isolation and culture: Primary WT and dKO non-myogenic mesenchymal stem 
cells (nmMSCs) and muscle derived stem cells (MDSCs) were isolated from 1 - 8 week old WT 
and dKO mice using a modified preplate method previously described (56, 74, 166). Briefly, 
after enzymatic digestion of skeletal muscle tissue, muscle derived cells were re-plated on 
collagen type I (C9791, Sigma-Aldrich) coated flasks over a period of days. Two hours after 
isolation, a rapidly adhering cell population was collected and characterized as nmMSCs. Seven 
days after preplating, a slowly adhering cell population was obtained, which has been described 
to contain the MDSC fraction of cells (75). nmMSCs and MDSCs were cultured in proliferation 
medium (PM) containing 10% fetal bovine serum, 10% horse serum, 0.5% chick embryo extract 
and 1% Penicillin-Streptomycin in Dulbecco’s modified Eagle’s medium (DMEM, 11995-073, 
Invitrogen) 
Immunophenotyping: Flow cytometry was performed on WT- and dKO-nmMSCs at the 
end of their third expansion passage. One-hundred thousand WT and dKO nmMSCs were 
collected, washed with PBS containing 2% FBS, centrifuged, and then placed on ice. The cells 
were then re-suspended in a 1:10 dilution of mouse serum (M5905, Sigma-Aldrich) in PBS and 
incubated for 10 minutes. PE-conjugated rat anti-PDGFRα (12140181, eBioscience), PE-
conjugated rat anti-Sca-1 (553108, BD), FITC-conjugated rat anti-CD34 (553733, BD), APC-
conjugated rat anti-CD90 (553007, BD), PE-conjugated rat anti-CD105 (562759, BD), and 
FITC-conjugated rat anti-CD45 (553080, BD) were added to each tube (1µl/100,000 cells) and 
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incubated for 30 minutes on ice. Only one antibody was used in each tube. The cells were then 
rinsed in 300µl of cold washing buffer (2% FBS in PBS, 4 degrees). A single color antibody was 
used to optimize fluorescence compensation settings for multicolor analyses.  
Immunofluorescence and histology: Muscle cryosections were fixed with 5% formalin 
for 8 minutes and blocked with 10% donkey serum for 1 hour. Slides were then incubated with 
goat anti PDGFRα (1:100, R&D) and rabbit anti-mouse Ki67 (1:200, Abcam) or chicken anti-
mouse laminin (1:500, Abcam) in 5% donkey serum. Next, sections were incubated with 
secondary antibodies including Alexa594-conjugated anti-rabbit IgG (1:300, Invitrogen), 
Alexa594-conjugated anti-chicken IgG (1:300, Invitrogen), or Alexa488-conjugated anti-goat 
IgG (1:300, Invitrogen) in PBS for 45 minutes.  
Differentiation Assays  
Adipogenic and osteogenic differentiation assays: Adipogenic and osteogenic 
differentiation was performed as described in Chapter 2. After differentiation, adipogenic cells 
were stained with rabbit anti-PPARγ (1:200, Cell Signaling) or goat anti-C/EBPα (1:50, Santa 
Cruz Biotechonology) in 5% donkey serum in PBS. 
Myogenic differentiation: 30,000 cells were plated on 24-well plates in DMEM 
supplemented with 2% FBS (Fusion medium, FM) to stimulate myotube formation. Three days 
after differentiation, the cells were fixed with 10% formalin for 8 min, and stained for fast 
myosin heavy chain (fMyHC) using a mouse anti-MyCHf antibody (1:250, M4276, Sigma-
Aldrich). The primary antibody was detected using a mouse-on-mouse (M.O.M) staining kit 
(Vector Labs, Burlingame, CA), according to manufacturer’s directions.  
Fibrogenic differentiation: 10,000 cells were plated on 24-well plates in PM 
supplemented with TGFβ1 (5ng/mL, R&D) for 3-5 days. After differentiation, fibrotic cells were 
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stained with mouse anti-collagen I (1:400, Abcam) using a M.O.M kit or rabbit anti-collagen III 
(1:500, Abcam) in 5% donkey serum.  
mRNA analysis was performed via reverse transcriptase polymerase chain reaction 
(RT-PCR): Total RNA was obtained from nmMSCs, MDSCs and gastrocnemius muscle tissues 
isolated from 6-8 week old WT animals using Trizol reagent (Invitrogen) and a RNeasy Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s instructions. Reverse transcription was 
performed using a Maxima first strand cDNA synthesis kit (Fermentas) according to the 
manufacturer’s protocol. PCR reactions were performed using an iCycler Thermal Cycler (Bio-
Rad) as previously described (24). Realtime RT-PCR was carried out using a Maxima Syber 
Green Assay kit (Thermo Scientific) in an iQ5 thermocycler (Bio Rad). Primers used in the study 
can be found in Table 2. 
Cell proliferation: To compare the proliferative potentials of the WT and dKO-
nmMSCs, a Live Cell Imaging system (LCI) (Kairos Instruments LLC) was used as previously 
described (185). In triplicate, 5000 nmMSCs per well were plated in a 24 well plate and 
incubated in a biobox incubator that sits atop a Nikon Eclipse TE 2000 U microscope stage 
equipped with a CCD camera. 10x bright field images were taken at fifteen minute intervals over 
a 72 hour period. Three locations were randomly chosen per well for imaging, capturing 9 fields 
of view per population, per experiment.  To measure the proliferation rates the LCI was used to 
capture images of different fields in each of the cultures over a 72 hour period. The number of 
cells per field of view at 12 hours intervals was determined using ImageJ software (National 
Institutes of Health, Bethesda, MD, USA). 
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Table 3. Primer sequences used in Chapter 3. 
 
 Myogenic co-culture experiments: dKO-MDSCs were plated in the lower compartment 
of Transwell Permeable Supports (Costar) in PM media at a density of 30,000 cells per well. 
WT- and dKO-nmMSCs were seeded onto 6.5mm transwell membrane inserts at the same 
density in PM media and placed above the dKO-MDSCs. As a control, each plate contained 
wells of dKO-MDSCs without transwell membrane inserts. To measure differentiation, the PM 
Gene Forward primer Reverse primer Size 
β-actin CCACACCCGCCACCAGTTCG TACAGCCCGGGGAGCATCGT 111 
Pax7 GTGCCCTCAGTGAGTTCGAT CCACATCTGAGCCCTCATCC 203 
Pax3 ACCCAAGCAGGTGACAACG CTAGATCCGCCTCCTCCTCT 168 
Myf5 GTCAACCAAGCTTTCGAGACG CGGAGCTTTTATCTGCAGCAC 306 
MyoD TACCCAAGGTGGAGATCCTG CATCATGCCATCAGAGCAGT 200 
Myogenin AGATTGTGGGCGTCTGTAGG CTACAGGCCTTGCTCAGCTC 199 
MyHC AGGACGACTGCAGACCGAAT CCCTCTGCAGTTCAGCCTTTACTTCC 157 
eMyHC GGAGGCTGATGAACAAGCCA GCTAGAGGTGAAGTCACGGG 141 
PPARγ TTGCTGAACGTAAGCCCATCGAGG GTCCTTGTAGATCTCCTGGAGCAG 228 
C/EBPα GCCGAGATAAAGCCAAACAAC GACCCGAAACCATCCTCTG 248 
OPN AGCAAGAAACTCTTCCAAGCAA GTGAGATTCGTCAGATTCATCCG 111 
OCN CTGACCTCACAGATCCCAAGC TGGTCTGATAGCTCGTCACAAG 165 
RUNX2 GACTGTGGTTACCGTCATGGC ACTTGGTTTTTCATAACAGCGGA 83 
Col1a TCATCGTGGCTTCTCTGGTC GACCGTTGAGTCCGTCTTTG 142 
Col3a ACGTAAGCACTGGTGGACAGA ACGTAAGCACTGGTGGACAGA 20 
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media was switched to FM. After 3 days, myogenic differentiation of the dKO-MDSCs was 
analyzed via immunostaining for fMyHC, as described above.  
Statistical analysis: Data from ≥ 4 samples from each subject were pooled for statistical 
analysis. Results are given as means ± SD. Statistical significance of any difference was 
calculated using Student’s t test. Values of p < 0.05 were considered statistically significant.  
 
3.3 RESULTS 
Rapid accumulation of lipids, calcium deposits, and fibrosis during the disease progression in 
the skeletal muscles of dKO mice.  
Previously, we reported that the onset of muscular dystrophy in the dKO mice occurred 
as early as 5 days of age and dystrophic histopathology became progressively worse by 6-8 
weeks of age. At this age, we also observed that the accumulation of connective tissue, ectopic 
calcium and fat deposits in the gastrocnemius muscles (GAS) of the dKO mice were 
substantially increased compared to that of age-matched WT-GAS (24, 56). To determine the 
age of onset of these events, the GAS from 1, 4 and 6-8 week old dKO mice were examined. Oil 
Red O, Alizarin Red, and Trichrome staining indicated that the accumulation of fat, calcium 
deposits and fibrosis started to occur in the GAS by 4 weeks of age and the severity of the 
histopathology increased substantially by 6-8 weeks of age in the dKO mice. There was a higher 
level of lipid accumulation observed in the 4 week old dKO-GAS compared to that of the 1 week 
old dKO-GAS, but lipid droplets were significantly increased in the GAS of 6 week old dKO 
mice compared to that of the 1 and 4week old dKO mice (Fig. 9A). Alizarin Red staining 
 53 
showed more extensive calcium deposition in the GAS of 4 and 6-8 week old dKO mice 
compared to that of the 1 week old GAS (Fig. 9B). We observed larger areas of fibrosis between 
the muscle fibers of 6-8 week old dKO-GAS compared to 1 week old dKO muscle (Fig. 9C). 
Very small amounts of lipid, calcium and fibrosis accumulation was observed in the 1 week old 
dKO GAS (Fig. 9A-C). GAS of 1, 4, and 6-8 week old dKO mice were collected and analyzed 
for mRNA expression of adipogenic (peroxisome proliferator-activated receptor gamma 
(PPARγ) and CCAAT/enhancer binding protein alpha (C/EBPα)), osteogenic (osteopontin 
(OPN), osteocalcin (OCN), and  runt-related transcription factor 2 (RUNX2)) and fibrogenic 
(collagen type 1 alpha (Col 1a) and collagen type 3 alpha (Col 3a)) markers by real time RT-
PCR (Fig. 9D). The expression levels of the markers in the 4 week old dKO-GAS were 
significantly higher than those in the 1 week old dKO-GAS, except OCN. Adipogenic, 
osteogenic, and fibrogenic markers in the 6-8 week old dKO-GAS were significantly up-
regulated compared to those in the 1 and 4 week old dKO-GAS. There were no significant 
differences in osteogenic (OPN and RUNX2) and fibrogenic (Col 1a) gene expressions between 
the 4 and 6 week old dKO-GAS. Taken together, our results demonstrated that the dKO mice 
rapidly developed skeletal muscle abnormalities that worsened with age which was similar to 
DMD patients (21, 22) .  
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Figure 9. Severe skeletal muscle pathologies including lipid accumulation, ectopic 
calcification, and development of fibrosis were observed in old dKO mice. 
 
(A) Oil Red O staining revealed the presence of lipid droplets in the gastrocnemius muscles of 1, 
4, and 6-8 week old dKO mice.  Severe lipid accumulation was observed in 6-8 week old dKO 
muscle (n>4). Scale bar = 100µm. (B) Alizarin Red staining showed calcium deposits in the 
dKO muscle sections. More extensive calcium deposits were detected in old dKO muscle (n>4). 
Scale bar = 100µm. (C) Trichrome staining was performed to identify fibrotic regions of the 
gastrocnemius of dKO mice. Increased fibrotic areas were observed in old dKO muscle (n>4). 
Scale bar = 100µm. (D) RNA was extracted from freshly collected muscle tissues of 1, 4, and 6-
8 week old dKO mice and  real time RT-PCR was performed (n>4) for PPARγ, C/EBPα, OPN, 
OCN, RUNX2, COL1a and COL3a mRNA expression. Error bars indicate ‘mean ± SD’. * p 
<0.05, ** p <0.001. 
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The phenotypic characterization of non-myogenic mesenchymal stem cells (nmMSCs) from 
dKO and WT mice. 
Next, we sought to determine what cell populations in the skeletal muscle were 
associated with the accumulation of lipid, calcium deposits and fibrosis in the dKO mice. 
Previously, we found that muscle progenitor cells (MPCs), including muscle derived stem cells 
(MDSCs) isolated from 6-8 week old dKO mice were defective in their proliferation capacities 
and adipogenic and osteogenic differentiation potentials (56); therefore, we searched for another 
population of skeletal muscle cells that were non-myogenic. Utilizing the preplate technique, 
rapidly adhering cells (RACs) were obtained, which we previously characterized as non-
myogenic mesenchymal stem cells (nmMSCs). Since adipocytes are thought to be derived from 
multipotent MSCs, we isolated nmMSCs from dKO mice and examined their behavior in 
dystrophic muscle.  
First, the immunophenotypes of the WT- and dKO-nmMSCs were compared using 
fluorescence-activated cell sorting (FACS) analysis using multiple MSC markers. The FACS 
results indicated that both the WT- and dKO-nmMSCs were positive for PDGFRα, CD90 and 
CD105 (markers reported to be expressed by mesenchymal cells) (91), and Sca-1. More than 
90% of the RACs from both WT and dKO mice were positive for CD34 (an endothelial cell 
marker) and less than 1% of the nmMSCs expressed CD45, a hematopoietic cell marker (Fig. 10 
A&B). Quantification of the FACS analysis indicated that there was no significant difference in 
the percentage of positive cells between the WT- and dKO-RACs for each of the markers tested 
(Fig. 10C).  
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Figure 10. WT- and dKO-nmMSCs expressed multiple mesenchymal stem cell markers. 
 
 
Freshly isolated (A) WT- and (B) dKO-nmMSCs were analyzed for multiple mesenchymal stem 
cell markers: PDGFRα, CD90, and CD105, a hematopoietic stem cell marker, CD45, and FAP 
markers, Sca-1 and CD34. (C) No statistically significant differences were observed in the 
percentage of marker expression between the WT and dKO cells (n=4). Error bars indicate 
‘mean ± SD’. 
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Proliferation and differentiation potentials of the nmMSCs are influenced by the disease 
progression in dKO mice.  
To test whether the disease progression in dKO mice was associated with changes in 
nmMSCs function, nmMSCs isolated from 1, 4, and 6-8 week old dKO skeletal muscle were 
compared for their proliferation and differentiation potentials. Using Live Cell Imaging (LCI), 
we observed that nmMSCs isolated from 1 week old dKO mice displayed significantly decreased 
proliferation rates compared to nmMSCs isolated from 4 and 6-8 week old dKO mice (Fig. 
11A). The population doubling time for 1 week old dKO-nmMSCs was approximately 44 hours, 
and 36 and 30 hours, respectively, for the 4 and 6-8 week old dKO-nmMSCs. More importantly, 
our results revealed that the 4 and 6-8 week old dKO-nmMSCs displayed significantly increased 
adipogenic/osteogenic potentials when compared to 1 week old dKO-nmMSCs (Fig. 11B-D). In 
addition, immunohistochemistry for PDGFRα (red) expression showed that the number of 
PDGFRα expressing cells was significantly higher in the 4 and 6-8 week old dKO-GAS when 
compared to the 1 week old dKO-GAS (Fig. 11E&F). There were no significant differences in 
the number of endogenous PDGFRα+ cells, in vitro proliferation rates, and differentiation 
potentials between the 4 and 6-8 week dKO-nmMSCs. Our results suggest that the nmMSCs are 
gradually activated with age in terms of their proliferation and adipogenic/osteogenic 
differentiation potentials as the disease progresses in the dKO mice.  Earlier, we showed that the 
accumulation of lipids, calcium deposits, and fibrotic tissue in the GAS of dKO mice started 
mildly at 1 week and became more severe as the mice grew older (Fig. 9A-C). Taking these all 
these results in to account, we propose that nmMSCs become activated as the histopathology of 
the dKO mice progresses, suggesting that they are involved in the deposition of the non-muscle 
tissues observed in the 6-8 week old dKO mice.    
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Figure 11. dKO-nmMSCs are progressively activated during the progression of the disease. 
(A) Comparison of proliferation rates of nmMSCs isolated from 1, 4, and  6 week old dKO mice 
(n=4). Error bars indicate ‘mean ± SD’. * p < 0.05, ** p < 0.001, ≠ p < 0.05.  (B) Adipogenic 
(top) and osteogenic (bottom) differentiation potentials of dKO-nmMSCs from different aged 
mice were compared. All scale bars = 50µm. (C) AdipoRed staining was performed for the 
detection of lipid accumulation in the cells (n>3). Error bars indicate ‘mean ± SD’. * p < 0.05. 
(D) Alkaline phosphatase activity was measured for the detection of calcium deposits (n>3). 
Error bars indicate ‘mean ± SD’. * p < 0.05. (E) Immunohistochemistry for PDGFRα expression 
(red) and dapi (blue) in the skeletal muscle of 1, 4, and 6-8 week old dKO mice (n=4). Scale bar 
=25µm. (F) Quantification indicating the percentage of cells that expressed PDGFRα. Error bars 
indicate ‘mean ± SD’. * p < 0.05. 
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 dKO-nmMSCs show enhanced proliferation and adipogenic, osteogenic, and fibrogenic 
potentials compared to age-matched WT-nmMSCs. 
 
Next, we compared the proliferation and differentiation potentials of nmMSCs isolated 
from 6-8 week old WT and dKO mice (Fig. 12). Surprisingly, LCI analysis of the in vitro 
proliferation rates of 6 week old WT- and dKO-nmMSCs showed that the dKO-nmMSCs 
displayed significantly greater proliferation rates than the WT-nmMSCs (Fig. 12A). We next 
examined the in vivo proliferation rates of the nmMSCs by performing immunohistochemistry 
for PDGFRα and Ki67, a proliferation marker, in the GAS of 6 week old WT and dKO mice. 
PDGFRα+ nmMSCs were localized in the interstitial spaces between the muscle fibers (Fig. 
12B). Our results indicated that the number of actively proliferating Ki67+PDGFRα+ nmMSCs 
was ~15-fold higher in the dKO skeletal muscle when compared to the age-matched WT muscles 
(Fig. 12C). We next investigated if the actively proliferating dKO-nmMSCs demonstrated an 
increase in their multilineage differentiation capacities. Our results indicated significant 
increases in the adipogenic (Fig. 12D), osteogenic (Fig. 12E), and fibrogenic differentiation (Fig. 
12F) capacities of the nmMSCs isolated from 6 week old dKO mice compared to those isolated 
from age-matched WT mice. Upon quantification, dKO-nmMSCs exhibited a 4-fold higher 
adipogenic differentiation potential and 3.5-fold higher osteogenic potential when compared to 
the age-matched WT-nmMSCs. In addition, WT- and dKO-nmMSCs readily differentiated into 
Collagen I (Col I) - and Collagen III (Col III) –expressing cells under fibrogenic culture 
conditions. Adipogenic and fibrogenic differentiation were further evaluated by immunostaining 
of Col I and Col III for fibrogenic cells, and PPARγ and C/EBPα for adipocytes (Fig. 12F). We 
found that there were more Col I- and Col III-positive cells in the dKO-nmMSC cultures 
compared to the WT-nmMSC cultures after fibrogenic induction. We also observed a significant 
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increase in the number of PPARγ- and C/EBPα-positive cells in the dKO-nmMSC cultures 
compared to the WT-nmMSC cultures, after 6 days of adipogenic induction (Fig. 12F&G).  Our 
results demonstrated that the function of the nmMSCs isolated from dKO mice were enhanced 
(increased proliferation and adipogenic, osteogenic, and fibrogenic differentiation potentials) 
when compared to their WT counterparts. 
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Figure 12. Proliferation and differentiation potentials of dKO-nmMSCs were significantly 
enhanced compared to that of age-matched WT-nmMSCs. 
 
(A) Comparison of cell proliferation of WT- and dKO-nmMSCs from the skeletal muscle of 6-8 
week old mice were investigated (n=4). (B) Immunostaining for PDGFRα (green) and Ki67 (red) 
in the skeletal muscle of 6 week old WT and dKO mice. Immunofluorescent images were 
merged with bright field images (n=4). Scale bar = 25µm. (C) Quantification indicating the 
percentage of cells expressing PDGFRα only, PDGFRα and Ki67, and Ki67 only. (D) 
Comparison of adipogenic and (E) osteogenic potentials of WT- and dKO-nmMSCs from 6 
week old mice (n=4). Scale bar =50µm. (F) WT- and dKO-nmMSCs were treated with TGFβ1 
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for 3-5 days or adipogenic induction medium for 6 days and the number of Col I (red) and Col 
III (green) or PPARγ (red) and C/EBPα (green) expressing cells were examined. Scale bars = 
50µm for Col I and Col III. Scale bars = 25µm for or PPARγ and C/EBPα. Immunostaining 
images were merged with bright field images. (G) Fibrogenic and adipogenic differentiation 
were evaluated by quantifying the percentages of Col I -, Col III-, and PPARγ-, C/EBPα -
positive cells. For all graphs, error bars indicate ‘mean ± SD’. * p < 0.05, ** p < 0.001. 
 
 
Activated dKO-nmMSCs inhibit myotube formation of age-matched dKO-MDSCs.  
Since the numbers of endogenous proliferating nmMSCs in the interstitial spaces of the 
GAS of 6-8 week old dKO mice were significantly increased compared to age-matched WT-
GAS (Fig. 5B), we examined the possibility that these cells might play a role in the development 
of the dystrophic phenotype by influencing the MDSCs. Cross-talk between MDSCs and 
nmMSC was tested to see if the nmMSCs could influence the myogenic differentiation potential 
of the MDSCs through a paracrine mechanism. MDSCs isolated from 6-8 week old dKO mice 
were co-cultured with age-matched WT- and dKO-nmMSCs using a transwell system, and the 
fusion index of the dKO-MDSCs was monitored. WT-nmMSCs were used as the control. To 
quantify the reduction in myogenic differentiation potential after co-cultivation, dKO-MDSCs 
were collected and immunostained for the terminal myogenic differentiation marker fMyHC. 
When dKO-MDSCs were co-cultured with WT-nmMSCs, the myogenic potential of the dKO-
MDSCs was significantly enhanced (Fig. 13A), as previously described (73, 92, 93, 107). 
Surprisingly, the limited myogenic potential of the dKO-MDSCs was further exacerbated after 
co-culturing with the dKO-nmMSCs (Fig. 13A).  fMyHC expressing cells were dramatically 
decreased when dKO-MDSCs were cultured in the presence of dKO-nmMSCs compared to the 
dKO-MDSCs alone (Fig. 13B). To rule out the possibility that the decrease in the dKO-MDSCs 
differentiation capacity was caused by the nmMSCs and not a secondary effect to a reduction in 
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dKO-MDSC proliferation, we measured the effect of co-cultivation of the dKO-MDSCs with 
dKO-nmMSCs on cell proliferation of the dKO-MDSCs using an MTS assay. No significant 
difference in proliferation was observed between the dKO-MDSCs alone and dKO-MDSCs co-
cultured with dKO-nmMSCs during the first 2 days of co-culture (Fig. 13C). Next, we further 
analyzed changes in the expression of myogenic markers expressed by the dKO-MDSCs after 3-
4 days of culturing in differentiation induction media with/without dKO-nmMSC co-cultivation, 
using real time RT-PCR. We observed a significant reduction in the expression of the myogenic 
markers, MyoD, Myogenin, eMyHC and fMyHC in the dKO-MDSCs in the presence of dKO-
nmMSCs (Fig. 13D). These results suggest that nmMSCs isolated from 6-8 week old dKO mice 
further inhibited the differentiation potential of age-matched dKO-MDSCs via an unknown 
secreted factor(s).    
One interesting observation from our in vivo studies was that the number of endogenous 
PDGFRα+ nmMSCs was almost 3 fold higher in 6-8 week old dKO skeletal muscle compared to 
that of the age-matched WT skeletal muscle (Fig. 12C). To mimic the in vivo dKO muscle 
micro-environment in our co-culture assay, we repeated the co-cultivation experiments above 
using 3:1, 1:1 and 1:6 ratios of dKO-nmMSCs to dKO-MDSCs. With a 3:1 ratio, we observed a 
larger effect of nmMSCs myogenic inhibition of the dKO-MDSCs compared to the 1:6 ratio. In 
fact, there was no significant difference in the formation of fMyHC expressing myotubes 
between the dKO-MDSCs only and dKO-MDSCs in the 1:6 ratio co-cultures (Fig. 13 E&F). 
Taken together, these results suggest that signals originating from nmMSCs contribute to the 
microenvironment’s ability to limit the myogenic differentiation capacity of the MDSCs in the 
dKO muscle.  
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Figure 13. Limited myogenic potential of 6 week old dKO-MDSCs was further exacerbated 
by co-culturing the cells with 6 week old dKO-nmMSCs. 
 
(A) Myogenic differentiation capacities were tested by co-cultivating WT- or dKO-nmMSCs 
with dKO-MDSCs using collagen type I coated transwell inserts. Immunohistochemistry for 
fMyHC was then performed for the detection of myotube formation. Dapi was used for 
counterstaining. Scale bar =50µm. (B) Quantification of the percentage of myotubes formed by 
the dKO-MDSCs after 3 days of myogenic differentiation with/without WT/dKO- nmMSCs co-
cultivation (n>4). Error bars indicate ‘mean ± SD’. ** p < 0.001. (C) MTS-based cell 
proliferation assay of dKO-MDSCs during first 48 hours of co-cultivation with/without dKO-
nmMSCs. (D) Real time RT-PCR analysis was performed and myogenic gene expression was 
compared between the dKO-MDSCs co-cultivated with/without dKO-nmMSCs (n>4). Error bars 
indicate ‘mean ± SD’. * p < 0.05, ** p < 0.001. (E) Co-culture myogenic differentiation 
experiments were done using 3:1, 1:1 and 1:6 ratios of dKO-nmMSCs to dKO-MDSCs. Scale 
bar =50µm. (F) Quantification of the percentage of myotubes formed by the dKO-MDSCs after 3 
days of myogenic differentiation with 3:1, 1:1 and 1:6 ratios of dKO-nmMSCs to dKO-MDSCs 
co-cultivation (n=3). Error bars indicate ‘mean ± SD’. * p < 0.05, ** p < 0.001.   
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3.4 DISCUSSION 
Despite the fact that the underlying pathogenesis of DMD has been well studied, treatment 
options remain limited for that disease. Traditionally available treatments for DMD patients 
include cell, gene, and protein-mediated therapies to restore dystrophin; however, these 
technologies have major limitations (20, 25, 186). For instance, accumulation of intramuscular 
fat, calcium deposits, and fibrotic tissue significantly limits the success of these regenerative 
approaches for DMD patients (6, 44, 94, 187). In the current study, we showed that the 
accumulation of lipid, calcium deposits, and fibrotic tissue coincide with the progressive 
reduction in muscle regeneration in the skeletal muscle of dKO mice. The histopathology and 
skeletal muscle abnormalities remain mild by the age of 1 week, but progressively worsen by 4 
and 6-8 weeks of age and consequently leads to death by 8-10 weeks of age. The development of 
intramuscular non-muscle tissue reduces muscle homeostasis and limits the potential for muscle 
regeneration (23). Therefore, the use of dystrophin replacement alone to treat the primary defect 
in DMD patients may not be successful for rescuing muscle from progressive degeneration and 
wasting, especially when performed at later stages of the disease (20, 25).  
When searching for potential cell sources responsible for the accumulation of ectopic 
non-muscle tissues in dystrophic muscle, we considered resident skeletal muscle non-myogenic 
mesenchymal stem cells (nmMSCs), which can be isolated from the tissue via the preplate 
technique. We have previously reported that MPCs isolated from aged dKO mice progressively 
become defective in their proliferation and differentiation capacities, including myogenic, 
osteogenic, adipogenic and chondrogenic capacities (56). In the current study, we demonstrated 
that the function of the nmMSCs in 6-8 week old dKO mice appeared to be enhanced during 
disease progression. Six week old dKO mice displayed a significant increase in nmMSCs in their 
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GAS compared to age matched WT mice. Moreover, nmMSCs isolated from 6 week old dKO 
mice displayed increases in their in vitro proliferation and adipogenic, osteogenic, and fibrogenic 
differentiation potentials compared to age-matched WT-nmMSCs. More importantly, the 
proliferation and differentiation potentials of dKO-nmMSCs isolated from 1 week old dKO mice 
appeared to not be affected, but gradually became activated by 4 weeks and started to extensively 
proliferate and demonstrated an increase in adipogenic/osteogenic differentiation capacities by 6-
8 weeks of age. These results taken together suggest that, the activation of the nmMSCs in the 
dKO mice might be involved with the occurrence of lipid and calcium deposition, and the 
formation of fibrotic tissue in the dKO muscle. Although it is not clear which event occurs 
initially, we posit that the activation of the nmMSCs is responsible for the accumulation of non-
muscle tissues during the disease progression in dKO mice, and this in turn, influences the 
muscle micro milieu, which further alters the myogenic potential of the MDSCs.  
Furthermore, the difference in proliferation and differentiation potentials among the 1, 4, 
and 6-8 week old dKO-nmMSCs suggests that the activation of nmMSCs in the aged dKO mice 
may not be caused by intrinsic differences, but by the changes in their microenvironment. This 
result is supported by a recently published study which reported that, the expression of 
transforming growth factor-β2 (TGFβ2) was induced in mdx muscle and this in turn further 
affected the behavior of muscle stem cells to become more pro-fibrogenic (95). This suggests 
that the local changes in the micro-milieu are responsible for stem cell dysfunction in dystrophic 
muscle. Therefore, we believe that the muscle environmental cues in the dKO mice influence the 
nmMSCs and likely play a role in determining stem cell fate.  
Recently, using a FACS-based cell isolation method, two research groups identified 2 
populations of resident skeletal muscle progenitor cells; 1) fibro/adipogenic progenitors (FAPs) 
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which express Sca-1 and CD34, and 2) PDGFRα+ mesenchymal stem/progenitor cells (MSCs). 
Both the FAPs and PDGFRα+ cells displayed high adipogenic and fibrogenic potentials in a 
glycerol-injected fatty degeneration model and in mdx mice (44, 73, 94). However, since mdx 
mice have a relatively normal life span and mild clinical features of the disease until very late in 
their life (51), our group utilized the dKO mouse model, which exhibits numerous clinically-
relevant manifestations and life-threatening features similar to DMD patients. The current study 
results utilizing the dKO mouse model support the contention that PDGFRα and Sca-1 
expressing nmMSCs are highly proliferative and have highly enhanced adipogenic /osteogenic 
potentials, which are likely associated with the deposition of lipid, calcification, and fibrosis in 
the dystrophic muscle of the mice during the progression of the disease.  
Wosczyna et al. also reported that functionally and phenotypically similar muscle 
resident mesenchymal progenitor cells expressing the angiopoietin receptor (Tie2), PDGFRα, 
and Sca-1 cell surface markers, exhibit robust BMP-dependent osteogenic activity and mediate 
heterotopic ossification in mice that have experienced a traumatic injury (106). Knowing that 
Tie2+ cells (106), FAPs (73), PDGFRα+ MSCs (44) and nmMSCs share the same surface 
markers, anatomical location in the muscle, and trilineage differentiation potentials, we postulate 
that they may represent the same population of cells.  
According to recent studies, these nmMSCs appear to possess dual roles, in addition to 
their involvement in muscle pathogenesis, and influence the myogenic potential of MPCs (44, 
73, 92, 93, 107). Previously, we observed that the MPCs, including MDSCs, isolated from dKO 
mice displayed a significantly reduced myogenic potentials compared to age-matched WT cells 
(56). Therefore, we further investigated if the interaction between activated nmMSCs and the 
MDSCs contributed to the loss of function of the dKO-MDSCs. Co-culture experiments revealed 
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that proliferating dKO-nmMSCs significantly limited the myogenic differentiation potential, but 
not the proliferation rate, of the dKO-MDSCs. In addition, our results suggest that effect is 
mediated by down-regulation of genes that are critical for myoblast maturation and terminal 
myogenic differentiation, including MyoD, myogenin, eMyHC and MyHC. Interestingly, by 
decreasing the number of nmMSCs co-cultured with the dKO-MDSCs, the MDSCs could be 
rescued from the inhibitory effects of the nmMSCs. Therefore, knowing that dKO mice suffer 
from constant muscle wasting and degeneration, we posit that the extensive proliferation of the 
nmMSCs in the dKO mice may be a source of trophic signals for hindering muscle regeneration 
during the chronic disease progression of DMD. 
FAPs’ involvement in inhibiting the MPCs myogenic potential had also been described in 
a study by Mozzetta et al. where they reported that FAPs isolated from old mdx mice repressed 
satellite cell-mediated myofiber regeneration (93). Of note, although young mdx mice exhibited 
successful muscle regeneration and very mild symptoms of DMD, old mdx mice (18 months and 
older) exhibit severe muscle fibrosis (188), which is similar to what is seen more rapidly in the 
dKO mice and is more similar to what is seen in DMD patients. Our results suggest that 
nmMSCs isolated from 6 week old dKO mice are functionally equivalent to that of 18 month old 
mdx mice, which supports our previous findings that propose the dKO mouse as a severe model 
of muscular dystrophy with accelerated disease progression compared to mdx mice (55). 
Recent studies suggest that skeletal muscle fibroblasts maybe the main source of 
intramuscular adipocytes in pathological conditions, including obesity, sarcopenia, and muscular 
dystrophies (189) and that their interactions with satellite cells are important for muscle 
regeneration (107). Murphy et al. showed that during muscle regeneration after injury, cells 
expressing transcription factor 4 (Tcf4) - a marker for fibroblasts - extensively proliferate in 
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close proximity to satellite cells and regenerating myofibers, and that the ablation of Tcf4+ cells 
leads to premature satellite cell differentiation and depletion of the early satellite cell pool (107). 
In turn, ablation of Pax7+ cells results in a complete loss of muscle regeneration capacity and a 
significant increase in connective tissue (107), suggesting that interactions between satellite cells 
and fibroblasts are critical for maintaining normal muscle homeostasis during regeneration. 
Agley et al., showed that TE-7+ human skeletal muscle fibroblasts, but not myogenic cells, 
readily undergo adipogenic differentiation (189). Interestingly, both Tcf4 and TE-7 expressing 
fibroblasts are rapidly adhering cells (adhering to the culture dish in 2-72 hours) and are also 
positive for the PDGFRα antigen. When we compare the morphology, early adhering 
characteristics, marker profile, anatomical locations, differentiation potentials, and the role that 
the TE-7+/Tcf4+ fibroblasts and nmMSCs/FAPs play in muscle regeneration, it appears that 
fibroblasts and mesenchymal stem cells have more in common than previously reported. Taking 
this into account, these populations of cells may actually represent the same cell population; 
however, further studies need to be performed to compare the relationship between fibroblasts 
and nmMSCs.  
Overall, our data suggests that compared to age matched WT-nmMSCs, nmMSCs 
isolated from 6-8 week old dKO mice are highly proliferative and their propensity for adipogenic, 
osteogenic, and fibrogenic differentiation is greatly increased. We therefore believe that the 
activation of nmMSCs coincides with the occurrence of fatty infiltration, ectopic calcification, 
and fibrotic tissue accumulation in the skeletal muscle of dKO mice. More importantly, we 
demonstrated that the nmMSCs represent a major contributor to the formation of ectopic fat, 
calcification, and fibrosis in the skeletal muscle of dKO mice, and that the activation of the 
nmMSCs may exacerbate the regeneration of the dystrophic muscle by inhibiting the myogenic 
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potential of MDSCs.  Results from this study could provide insights into new approaches to 
alleviate muscle weakness and wasting in DMD patients by targeting nmMSCs during the 
disease process.   
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4.0  ADIPOGENIC DYSTROPHIC MUSCLE MICROENVIRONMENT INDUCES A 
CHANGE IN THE NON-MYOGENIC MESENCHYMAL STEM CELL ACTIVITY 
4.1 INTRODUCTION 
Figures 18&20 of Chapter 4 are adapted from a published article in Human Molecular Genetics: 
Jihee Sohn1, Aiping Lu1, Ying Tang1, Bing Wang1, and Johnny Huard1,2*. (2015) Activation 
of non-myogenic mesenchymal stem cells during the disease progression in dystrophic 
dystrophin/utrophin knockout mice. Hum Mol Gen In press. 
1Stem Cell Research Center, Department of Orthopaedic Surgery, University of Pittsburgh, 
School of Medicine 
2Department of Microbiology and Molecular Genetics, University of Pittsburgh School of 
Medicine 
 
Muscle wasting is a serious clinical problem associated with various types of diseases and health 
conditions, affecting individuals of all ages (56, 95). Muscular dystrophy (MD) encompasses a 
heterogeneous group of about 40 different forms of muscle wasting disease resulting from 
genetic mutations. Duchenne muscular dystrophy (DMD) is the most common and severe form 
of MD and it is invariably fatal. (10). In the case of DMD, a structural muscle protein, dystrophin, 
is missing, and its absence leads to progressive wasting and degeneration of skeletal muscle. 
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Currently, there is no effective treatment to end or reverse DMD (11).  However, recent research 
studies suggest that cell/stem cell therapy might now offer some hope. Skeletal muscle is 
especially favorable to cell transplantation therapy since the mode of muscle repair and fiber 
formation is via the fusion of mononuclear cells, and transplanted donor cells can participate in 
this process (65). In addition, the stem cell secretome can simultaneously aid in reducing 
inflammation, which may slow the progress of the disease and increase the survival of 
transplanted donor cells. Indeed, myoblasts, mesoangioblasts, muscle-derived stem cells 
(MDSCs), bone-marrow derived mesenchymal stem cells (BM-MSCs), embryonic stem cells 
(ESCs), and induced pluripotent stem cells (iPSCs) have been reported to exhibit therapeutic 
potentials ameliorate dystrophic muscle pathology in DMD animal models (20, 65, 71).  
Stem cells are undifferentiated cells that can differentiate into specialized, mature cell 
types and self-renew (190). Therefore, understanding the mechanisms that underlie stem cell 
maintenance and differentiation is essential to increase the efficacy of stem cell use for various 
therapeutic applications. The phenotypic characterization and function of stem cells are largely 
governed by the physical properties of the microenvironment of each tissue, which direct key 
cellular decisions including cell division, migration, and differentiation of cells (112, 116). For a 
stem cell, this information represents important cue that instructs the cells to select a given cell 
fate that matches the physical surroundings. In DMD, skeletal muscle is often replaced by 
ectopic adipocytes, calcium deposits, and fibrotic tissues and with chronic inflammation these 
non-muscle tissues impair the function of the muscle fibers, leading to increasing weakness and 
stiffness (10, 24, 56, 191). Therefore, understanding the effects of dystrophic muscle milieu on 
stem cells survival and function are important considerations for treating DMD.  
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Numerous investigations including ours, have reported that changes in muscle milieu due 
to disease or injury may alter the behavior or fate of muscle progenitor cells (MPCs), including 
satellite cells (SCs), myoblasts, and muscle derived stem cells (MDSCs), and compromise their 
myogenic potentials (95, 102, 121, 122). In addition to MPCs, proliferation, survival, and 
differentiation abilities of resident mesenchymal stem/progenitor cells can also be affected by 
changes in muscle microenvironment. For example, mesenchymal stem/progenitor cells readily 
undergo adipo-/fibrogenesis and contribute to deposition of skeletal muscle adipose tissue and 
fibrosis in glycerol induced fatty degenerating or mdx skeletal muscles. Also shown is that these 
cells are quiescent and unable to survive or engraft post-transplantation in healthy, wild type 
(WT) muscles (73). A recent study from our lab also demonstrated that surrounding muscle 
microenvironment governs the proliferation and differentiation potentials of skeletal muscle 
resident non-myogenic mesenchymal stem cells (nmMSCs) (191).  
Utilizing dystrophin/utrophin double knockout, (dKO) mice, we demonstrated that 
muscle histopathology and muscular dystrophy in dKO mice started mildly at 1 week, but 
gradually became more severe as the mice grew older, at 6-8 week. Interestingly, we observed 
that the nmMSCs isolated from 6-8 week old dKO mice were activated in terms of their in vitro 
and in vivo proliferation and adipogenic/osteogenic potentials compared to age-matched WT 
cells. More importantly, when we compared the nmMSCs from 1-, 4-, and 6-8 week old dKO 
mice, the nmMSCs from 4 and 6-8 week old dKO mice displayed significantly increased 
proliferation and adipogenic/osteogenic potentials compared to 1 week old dKO-nmMSCs (191). 
Taken together, the difference in proliferation and differentiation potentials among the 1-, 4-, and 
6-8 week old dKO-nmMSCs indicates that the aberrant activation of the nmMSCs in the aged 
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dKO mice may not be caused by intrinsic differences, but rather by the changes in 
microenvironment due to the severity of the disease.  
In this investigation, we further examined the effects of muscle milieu on the nmMSCs 
function by comparing cellular activities of the nmMSCs isolated from two different muscle 
environments: 1) regenerating WT muscle injured with intramuscular injection of cardiotoxin 
(WT-CTX) (192), and 2) fibro-adipogenic degenerating dystrophic muscle. We found that the 
nmMSCs isolated from 6-8 week old WT-CTX and dKO mice exhibited similar proliferation and 
adipogenic/osteogenic differentiation potentials. We performed a co-culture assay to investigate 
how nmMSCs from WT-CTX and dKO mice would influence the myogenic potential of MDSCs 
through a paracrine mechanism. Interestingly, WT-CTX-nmMSCs significantly enhanced 
myogenic potential of the MDSCs while the dKO-nmMSCs strongly inhibited myotube 
formation of MDSCs. The inhibitory effect of the dKO-nmMSCs on dKO-MDSC myogenic 
potential was found to be mediated, at least in part, by the secretion of secreted frizzled-related 
protein 1 (sFRP1), a known inducer of adipogenesis as well as an inhibitor of myogenesis. Taken 
together, our data suggests that the activity of the nmMSCs in influencing MDSC myogenic 
potential may depend on the microenvironment which they reside in. We also provide new 
mechanistic insight into how the fibro-adipogenic degenerating dystrophic muscle milieu alters 
the stem cell function and demonstrated that increased expression of sFRP1 may contribute to 
dysfunction of the nmMSCs in chronic, degenerating muscle disease condition.  
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4.2 MATERIALS AND METHODS 
Animals: C57BL/10J (wild type; WT) mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). Dystrophin/utrophin knockout (dKO) mice, originally characterized by Deconinck 
and colleagues (51), were generated by crossing heterozygous dystrophin-/-; utrophin+/- mice 
(55, 184). Genotyping was performed by polymerase chain reaction (PCR) analysis of tail 
samples. Mice ranged in age from 3 to 8 weeks. Specific ages for each experiment are described 
below. All animal protocols used for these experiments were approved by the University of 
Pittsburgh’s Institutional Animal Care and Use Committee. 
Cardiotoxin muscle injury model: WT (6-8 weeks old) mice were injured by the 
injection of 120µL of cardiotoxin (4µM, CTX, sigma, St. Louis, MO), as previously described 
(192). The animals were sacrificed 3 days after CTX injection.  
Cell isolation and culture: Primary WT, WT-CTX, and dKO non-myogenic 
mesenchymal stem cells (nmMSCs) and muscle derived stem cells (MDSCs) were isolated from 
6-8 week old WT, WT-CTX, and dKO mice using a modified preplate method previously 
described (56, 74, 166). Briefly, after enzymatic digestion of skeletal muscle tissue, muscle 
derived cells were re-plated on collagen type I (C9791, Sigma-Aldrich) coated flasks over a 
period of days. Two hours after isolation, a rapidly adhering cell population was collected and 
characterized as nmMSCs. 6 days after preplating, a slowly adhering cell population was 
obtained, which has been described to contain the MDSC fraction of cells (75). nmMSCs and 
MDSCs were cultured in proliferation medium (PM) containing 10% fetal bovine serum, 10% 
horse serum, 0.5% chick embryo extract and 1% Penicillin-Streptomycin in Dulbecco’s modified 
Eagle’s medium (DMEM, 11995-073, Invitrogen). 
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Fluorescence activated cell sorting (FACS): Flow cytometry was performed on WT-
CTX-nmMSCs at the end of their third expansion passage. One-hundred thousand nmMSCs 
were collected, washed with PBS containing 2% FBS, centrifuged, and then placed on ice. The 
cells were then re-suspended in a 1:10 dilution of mouse serum (M5905, Sigma-Aldrich) in PBS 
and incubated for 10 minutes. PE-conjugated rat anti-PDGFRα (12140181, eBioscience), PE-
conjugated rat anti-Sca-1 (553108, BD), and FITC-conjugated rat anti-CD45 (553080, BD) were 
added to each tube (1µl/100,000 cells) and incubated for 30 minutes on ice. Only one antibody 
was used in each tube. The cells were then rinsed in 300µl of cold washing buffer (2% FBS in 
PBS, 4 degrees). A single color antibody was used to optimize fluorescence compensation 
settings for multicolor analyses.  
Immunofluorescence and histology: 5000 WT-CTX- or dKO-nmMSCs were cultured 
on 48 well plates. Cells were fixed with 4% paraformaldehyde for 8 minutes and blocked with 
10% donkey serum for 1 hour. Slides were then incubated with goat anti-PDGFRα (1:100, R&D) 
in 5% donkey serum. Next, sections were incubated with secondary antibody, Alexa488-
conjugated anti-goat IgG (1:300, Invitrogen) in PBS for 45 minutes. Muscle cryosections were 
fixed with 4% paraformaldehyde for 8 minutes and blocked with 10% donkey serum for 1 hour. 
Slides were then incubated with rabbit anti-beta catenin (1:200, Abcam), goat anti-PDGFRα 
(1:100, R&D) and rabbit anti-mouse Ki67 (1:200, Abcam) in 5% donkey serum. Next, sections 
were incubated with secondary antibodies including Alexa594-conjugated anti-rabbit IgG (1:300, 
Invitrogen) or Alexa488-conjugated anti-goat IgG (1:300, Invitrogen) in PBS for 45 minutes.  
Proliferation assay: Cells were plated in 24-well plates at an initial density of 1000 
cells/cm2. Cell number at the prescribed time points was determined on the basis of dsDNA 
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concentration using the PicoGreen assay (Life technologies, Grand Island, NY, USA), and the 
doubling time was estimated using an exponential fit.   
Myogenic differentiation and co-culture experiments: WT-CTX- and dKO-nmMSCs 
were co-cultured using transwell insert as described in Chapter 3. Cells were exposed to a 
neutralizing antibody against sFRP1 (Abcam) at the final concentration of 1- or 10µM.  
MTS assay for MDSCs proliferation: The CellTiter 96 Aqueous One Solution Assay 
(Promega, Madison, WI), which is a colorimetric method for determining the number of viable 
cells in proliferation was used. 30,000 cells were plated in triplet on 24-well plate and 48 hour 
after CellTiter 96 AQueous One Solution was added (20µl/100µl PM). Plate was incubated for 4 
hours and the absorbance at 490nm was read using plate reader.  
 Detection of sFRP1 secretion in nmMSCs: The amount of secreted frizzled-related 
protein 1 (sFRP1) from WT-CTX- and dKO-nmMSC cultures was measured with a mouse 
sFRP1 ELISA kit (MBS756370, MyBioSource) according to the manufacturer’s instructions. 
Briefly, nmMSCs from 6 week old WT-CTX or dKO mice were plated on 6 well plates, in 
triplicate, and incubated in PM. 24 hours after initial plating, the cells were washed three times 
with PBS and PM was switched with serum free DMEM. 24 hours after switching to the serum 
free medium, the cell culture supernatants were collected and used to perform the ELISA for the 
sFRP1 protein. The results were immediately determined by comparing the Optical Density 
(O.D.) at 450 nm using a microplate reader (Infinite M200, TECAM, Inc.).  
mRNA analysis was performed via reverse transcriptase polymerase chain reaction 
(RT-PCR): Total RNA was obtained from nmMSCs and gastrocnemius muscle tissues isolated 
from 6-8 week old WT-CTX and dKO animals using TRizol reagent (Invitrogen) and a RNeasy 
Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Reverse 
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transcription was performed using a Maxima first strand cDNA synthesis kit (Fermentas) 
according to the manufacturer’s protocol. PCR reactions were performed using an iCycler 
Thermal Cycler (Bio-Rad) as previously described (24). Realtime RT-PCR was carried out using 
a Maxima Syber Green Assay kit (Thermo Scientific) in an iQ5 thermocycler (Bio Rad). Primers 
used in the study can be found in Table 3. 
Axin2 CAGAGGGACAGGAACCACTC TGCCAGTTTCTTTGGCTCTT 101 
LGR5 TCGCCTTCCCCAGGTCCCTTC GCCGTGGTCCACACCCCGAT 79 
Table 4. Primer sequences used in Chapter 4. 
Western Blot: Tissue lysates were prepared in RIPA buffer (Sigma) supplemented with 
protease and phosphatase inhibitors (1:100, Sigma) and quantified using the Bio Rad Protein 
Assay (500-0001, Bio Rad, Hercules, CA, USA). Immunoblotting was performed as previously 
described (12). Membranes were incubated with mouse monoclonal antibody to active-β-catenin 
(0.5µg/ml, Millipore, Temecula, CA) or rabbit polyclonal antibody to alpha tubulin (Abcam) at 
4°C overnight in 5% milk in TBST. Alpha tubulin was used to evaluate equal loading.  
Statistical analysis: Data from ≥4 samples from each subject were pooled for statistical 
analysis. Results are given as means ± SD. Statistical significance of any difference was 
calculated using Student’s t test. Values of p < 0.05 were considered statistically significant.  
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4.3 RESULTS 
Morphological characteristics of skeletal muscle regeneration. 
  Recently, we reported that the non-myogenic mesenchymal stem cells (nmMSCs) 
isolated from 6-8 week old dystrophic dKO mice were abnormally activated in their proliferation 
and differentiation potentials in comparison to their WT counterparts (191). Next, we examined 
whether changes in microenvironment would affect the function of nmMSCs by comparing 
cellular behaviors of the nmMSCs isolated from well-established cardiotoxin (WT-CTX) muscle 
injury mice (192) and dKO mice.  First, we collected gastrocnemius muscles (GAS) of 6-8 
weeks old WT mice 3 days post cardiotoxin injection and the age-matched dystrophic dKO mice.  
Hematoxylin and eosin (H&E) staining of tissue cross sections revealed that the WT-CTX 
muscle exhibited substantial histological evidence of the early events following muscle injury, 
when compared to age-matched WT muscle (Fig. 14A&B). CTX injections resulted in the rapid 
muscle fiber necrosis and increased number of non-muscle mononucleate cells within the 
damaged site, leading to the loss of muscle architecture (Fig. 14B). As we expected, dKO-GAS 
exhibited severe dystrophic muscle histopathology, including muscle damage, areas of myofiber 
necrosis, adipocyte infiltration, connective tissue deposition, and extensive mono-nuclei cell 
infiltration (Fig. 14C). Accumulation of adipose cells or increase in fibrosis was not observed in 
tissue sections of WT-CTX mice. These results suggest that there are differences in 
morphological characteristics of skeletal muscle and micro-milieu between regenerating injured 
muscles with direct trauma and diseased muscles with innate genetic defects.  
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Figure 14. Morphological characteristics of skeletal muscles from WT, WT-cardiotoxin 
injured mice, and dystrophic mice. 
 
Representative muscle sections of the 6-8 week old (A) WT, (B) WT-cardiotoxin injured mice 
(WT-CTX), and (C) dystrophic dKO mice. (B) Intra-muscular injection of cardiotoxin (CTX) in 
gastrocnemius muscle (GAS) resulted in rapid necrosis of myofibers and mono-nucleated cell 
infiltration. H&E staining of WT-CTX muscle section demonstrated the extent of tissue damage 
compared to age-matched WT muscles. (C) H&E staining of 6-8 week old dKO mice muscle 
sections showed severe dystrophic muscle histopathology.  
 
 
Isolation and phenotypic characterization of the non-myogenic mesenchymal stem cells from 
cardiotoxin injured skeletal muscle. 
Next, to examine the effect of microenvironment on nmMSC function, we isolated 
nmMSCs from WT-CTX and dKO skeletal muscles utilizing the modified preplate technique 
(74) and first compared their phenotypes. 2 hours after isolation, adherent WT-CTX-nmMSCs 
exhibited similar morphology as dKO-nmMSCs (Fig. 15B). 3-4 passages after, cells were 
labeled with antibodies against, PDGFRα, Sca-1, and CD45, and subsequently analyzed by flow 
cytometry. Our results demonstrated that isolated WT-CTX-nmMSCs were highly positive for 
PDGFRα and Sca-1, but were negative for CD45 (Fig. 15C&D). The immunophenotyping of 
WT-CTX-nmMSCs were very similar to that of dKO-nmMSCs (Chapter 3). We next examined 
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the expression of PDGFRα protein by immunostaining, and found no significant differences in 
the number of cells expressing PDGFRα protein between WT-CTX- and dKO-nmMSCs (Fig. 
15E&F). These results suggest that we successfully isolated the nmMSCs from WT-CTX 
regenerating muscle, and there was no difference in phenotypic characteristics between WT-
CTX and dKO cells.   
 
WT-CTX-nmMSCs and dKO-nmMSCs exhibited similar proliferation and differentiation 
capacities.    
Previously, we showed that the nmMSCs isolated from dKO mice were progressively 
activated during the disease progression. In addition, we reported that the proliferation and 
adipogenic, osteogenic, and fibrogenic differentiation potentials of dKO-nmMSCs were 
significantly enhanced compared to that of age-matched WT-nmMSCs (191), suggesting that 
disease muscle microenvironment may cause the aberrant proliferation and differentiation 
capacities of the nmMSCs.   Therefore, we next examined proliferation and differentiation 
potentials of the nmMSCs isolated from 6-8 week old WT-CTX. After isolation, cells were 
expanded in growth medium for 3-4 passages, and then transferred to 24 well plates, and 
proliferation was determined on the basis of dsDNA concentration at different time points 
measured with the PicoGreen assay. There was no significant difference in the proliferation rate 
of the WT-CTX-nmMSCs compared to dKO-nmMSCs, except at one time point. At day 7, 
proliferation rate of dKO-nmMSCs was slightly greater (Fig. 16A) than WT-CTX-nmMSCs. We 
also examined in vivo proliferation of the nmMSCs from GAS of WT-CTX and dKO mice by 
performing immunostaining for PDGFRα and Ki67, a proliferation maker. Dapi-labeled cells 
that were positive for both PDGFRα and Ki67 were quantified. Upon quantification, we 
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observed no significant difference in the number of PDGFRα+Ki67+ nmMSCs in GAS of WT-
CTX and dKO mice (Fig. 16B&C). Lastly, we compared adipogenic and osteogenic 
differentiation potentials of nmMSCs isolated from 6-8 week old WT-CTX and dKO muscles 
(Fig. 16D&E). 21 days after adipogenic induction, both WT-CTX- and dKO-nmMSCs showed 
extensive accumulation of lipids. 10 days after osteogenic induction, both cell types were 
positive for Alizarin Red, which indicated presence of calcium deposits. Upon quantification, we 
did not observe any differences in adipogenic or osteogenic potentials of WT-CTX- and dKO-
nmMSCs. These assays demonstrated similar proliferation and differentiation potentials between 
WT-CTX-nmMSCs and dKO-nmMSCs. 
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Figure 15. Phenotypic characterization of the nmMSCs isolated from WT-CTX skeletal 
muscle. 
 
(A) WT-CTX-nmMSCs morphology was similar to that of dKO-nmMSCs under phase contrast 
microscopy. (C) Fluorescence activated cell sorting (FACS) plots show that WT-CTX-nmMSCs 
were positive for PDGFRα and Sca-1, but were negative for CD45. (D) Quantification of FACS 
results. Error bars indicated ‘mean ± SD’, n=4. (E) Immunostaining for the mesenchymal stem 
cell marker PDGFRα was also performed. (F) Quantification of immunostaining of PDGFRα. 
All Scale bars =50µm. 
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Figure 16. WT-CTX-nmMSCs and dKO-nmMSCs displayed similar proliferation and 
differentiation potentials. 
  
(A) Proliferation rates of the nmMSCs isolated from WT-CTX- and dKO mice were assayed on 
the basis of dsDNA content for each time point, and no significant differences were detected, 
except for day 7. (n=4). Error bars indicate ‘mean ± SD’. (B) Immunohistochemistry for 
PDGFRα (green) and Ki67 (Red) expression in the skeletal muscle of 6-8 week old WT-CTX 
and dKO mice. (n=4). Scale bar = 25µm. (C) Quantification indicating the percentage of cells 
expressing PDGFRα and Ki67. Error bars indicate ‘mean ± SD’. (D) AdipoRed (adipogenesis) or 
Alizarin Red (osteogenesis) staining was performed after differentiation assays. Scale bar=50µm. 
(E) Quantification of adipogenesis (AdipoRed signal intensity was normalized to total Dapi 
signal intensity) and osteogenesis (relative ALP activity was normalized to total dsDNA content) 
indicated that there was no significant differences in adipogenic or osteogenic potentials between 
WT-CTX- and dKO-nmMSCs. (n=4). Error bars indicate ‘mean ± SD’.  
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Myogenic potential of muscle progenitor cells (MPCs) is increased by nmMSCs from 
regenerating muscle, but inhibited by nmMSCs from dystrophic muscle.  
In previous study, we showed that activated nmMSCs from dKO mice may contribute to 
continuous muscle wasting and degeneration by limiting myogenic potential of MPCs, especially 
muscle derived stem cells (MDSCs) (191). Since our results above indicated that WT-CTX-
nmMSCs were also highly proliferative 3 days after injury, we further tested whether the 
nmMSCs isolated from WT-CTX regenerating muscles could positively or negatively influence 
fusion potential of MDSCs. In contrast to fibro-adipogenic degenerating dKO muscle, WT-CTX 
regenerating muscle rarely induces fatty infiltration or fibrosis formation in the skeletal muscle. 
Therefore, it is expected that the behavior of the nmMSCs in WT-CTX-GAS is regulated in a 
manner distinct than dKO-nmMSCs. 6 week old dKO-MDSCs were co-cultured with age-
matched WT-CTX- or dKO-nmMSCs, using a transwell system, and the fusion index of the 
dKO-MDSCs was monitored (Fig. 17A). Consistently, dKO-nmMSCs impaired the 
differentiation ability of dKO-MDSCs (Fig. 17B). fMyHC expressing cells were dramatically 
decreased when dKO-MDSCs were cultured in the presence of the dKO-nmMSCs compared to 
the dKO-MDSCs alone (Fig. 17C). By contrast, the nmMSCs isolated from WT-CTX muscles, 
significantly enhanced the myotube formation of dKO-MDSCs after co-cultivation compared to 
dKO-MDSCs only (Fig. 17B&C). Proliferation rates of dKO-MDSCs without co-cultivation, co-
cultivation with WT-CTX-nmMSCs, or co-cultivation with the dKO-nmMSCs were compared 
using a MTS assay during first two days in growth medium. We observed no significant 
differences in proliferation rates among three groups, suggesting that reduction or enhancement 
of dKO-MDSCs’ myogenic potentials was not a secondary effect to the proliferation (Fig. 17D).  
Taken together, our data suggest that after CTX injury the nmMSCs are activated and undergo 
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extensive proliferation to promote repair/regeneration process by facilitating MPC myogenic 
differentiation. Furthermore, these results indicated that the nmMSCs derived from distinct 
muscle environments modulate the regenerative capacity of MDSCs in a different manner.    
 
 
 
Figure 17. The nmMSCs from WT-CTX mice enhance the in vitro differentiation potential 
of MDSCs. 
 
(A) Myogenic differentiation capacities were tested by co-cultivating WT-CTX- or dKO-
nmMSCs with dKO-MDSCs using collagen type I coated transwell inserts. (B) 
Immunohistochemistry for fMyHC was then performed for the detection of myotube formation. 
Dapi was used for counterstaining. Scale bar =50µm. (C) Quantification of the percentage of 
myotubes formed by the dKO-MDSCs after 3 days of myogenic differentiation with/without 
WT-CTX-/dKO- nmMSCs co-cultivation (n>4). Error bars indicate ‘mean ± SD’. ** p < 0.001. 
(D) MTS-based cell proliferation assay of dKO-MDSCs during first 48 hours of co-cultivation 
with/without dKO-nmMSCs. (n>4). Error bars indicate ‘mean ± SD’.  
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Myotube formation of dKO-MDSCs is inhibited by the secreted frizzled-related protein 1 
(sFRP1) released by the dKO-nmMSCs.  
It has been known that PDGFRα+ cells secrete follistatin to promote myogenic activity of 
muscle stem cells (satellite cells) in injured muscles (93); however, the soluble factor that is 
released from the nmMSCs to inhibit myogenic potential of MPCs in dKO muscles is unknown. 
In search of a soluble factor responsible for functional interactions between the nmMSCs and 
MDSCs from dKO mice, we considered secreted frizzled-related protein 1 (sFRP1) as a potential 
candidate. In fact, it has been previously shown that sFRP1 inhibits myotube formation of 
C2C12 and satellite cells, with no significant effect on the cell cycle or apoptosis (193). We 
performed real time RT-PCR to examine the sFRP1 mRNA expression from total GAS of 6-8 
week old WT-CTX- and dKO mice and values were normalized to sFRP1 mRNA expression of 
age-matched WT-GAS. We observed a significant increase in sFRP1 gene expression in the 
dKO-GAS compared to that of the WT-CTX-GAS (Fig. 18A). Next, we examined if the dKO-
nmMSCs expressed higher sFRP1 mRNA levels compared to that of WT-CTX-nmMSCs, which 
was confirmed by real time RT-PCR. sFRP1 gene expression was shown to be increased 
approximately 4.5 fold in the dKO-nmMSCs when compared with age-matched WT-CTX-
nmMSCs (Fig. 18B). sFRP1 is a secreted protein, therefore we next investigated if higher 
amounts of sFRP1 were secreted by the dKO-nmMSCs compared to the WT-CTX-nmMSCs. We 
collected cell culture supernatants from WT-CTX- and dKO-nmMSCs cultures and the levels of 
sFRP1 protein secreted from all cell types was assayed using a mouse specific sFRP1 ELISA kit. 
As expected, there was a significantly higher sFRP1 concentration in the cell culture 
supernatants isolated from the dKO-nmMSCs when compared to that of WT-CTX-nmMSCs 
(Fig. 18C). These results suggest that the secretion of sFRP1 from dKO-nmMSCs might be 
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responsible for inhibiting the myogenic differentiation of dKO-MDSCs as previously described 
(Fig. 17B&C).  
 
 
 
Figure 18. Higher sFRP1 expression was detected in dKO skeletal muscle when compared 
to WT-CTX muscle. dKO-nmMSCs secreted a higher level of sFRP1 than WT-CTX-
nmMSCs.  
 
RNA was extracted from frozen muscle tissue and real time RT-PCR was performed. Higher 
sFRP1 gene expression was observed from (A) dKO-GAS compared to age-matched WT-CTX-
GAS (n>4) and (B) 6 week old dKO-nmMSCs compared to age-matched WT-CTX-nmMSCs 
(n>4). All values were normalized to sFRP1 gene expression of WT-GAS or WT-nmMSCs. 
Error bars indicate ‘mean ± SD’. **p < 0.0001. (C) Concentration of secreted sFRP1 from WT- 
or dKO-nmMSCs was measured with a mouse sFRP1 ELISA kit. The graph represents sFRP1 
concentration per every 100,000 WT- or dKO-nmMSCs (n=6). Error bars indicate ‘mean ± SD’. 
**p < 0.005, **p < 0.0001.   
 
 
Blockade of secreted sFRP1 from the nmMSCs increases myogenic differentiation of dKO-
MDSCs co-cultured with dKO-nmMSCs. 
 To confirm the above finding, we tested whether blocking secreted sFRP1 in culture 
medium could enhance the myogenic potential of dKO-MDSCs co-cultivated with dKO-
nmMSCs. dKO-MDSCs were co-cultivated with dKO-nmMSCs and were exposed to 
differentiation medium containing neutralizing antibodies against sFRP1. In transwell co-culture 
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experiments, incubation of the dKO-nmMSCs with neutralizing antibodies against sFRP1 negate 
the inhibiting effect of the dKO-nmMSCs and significantly increased the formation of 
multinucleated myotubes from dKO-MDSCs (Fig. 19A&B). This effect was dose-dependent as 
we observed greater myotube formation when we treated dKO-nmMSCs with 10µM 
concentration of antibody compared to that of 1µM. This result supports the conclusion that 
nmMSCs-derived sFRP1 inhibits the regeneration potential of MPCs in dystrophic muscles.   
 
Wnt signaling is elevated in dKO muscle 
The results above suggest that the upregulation of sFRP1 in skeletal muscle may 
contribute to the dystrophic phenotype observed in dKO mice. In order to better understand the 
molecular events behind the upregulation of sFRP1, we further investigated if the Wnt signaling 
pathway was involved, since sFRP1 is the modulator of Wnt signaling pathway and elevated 
Wnt signaling in mdx mice has been reported by other research groups (95, 194). In Figure 18, 
we observed that sFRP1 mRNA expression of dKO-GAS was significantly higher compared to, 
not only WT-CTX-GAS, but also WT-GAS and WT-nmMSCs. Therefore, here, we compared 
the activation of Wnt signaling in WT- and dKO-GAS. Western blot demonstrated that the 
amount of dephosphorylated β-catenin (active form) was increased in 6-8 week old dKO-GAS 
compared to age-matched WT-GAS (Fig. 20A). Furthermore, we observed elevated β-catenin 
expression by immunofluorescence (Fig. 20B&C) and the increased mRNA expressions of 
Axin2 (Fig. 20D) and LGR5 (Fig. 20E), the downstream targets of the Wnt signaling pathway 
(4, 195), by real time RT-PCR in 6-8 week old dKO-GAS compared to age-matched WT-GAS. 
Our results suggest that Wnt signaling is increased in dystrophic dKO muscle.  
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Figure 19. dKO-nmMSCs treated with neutralizing antibodies against sFRP1 
increase dKO-MDSC myogenic potential. 
 
(A) MDSCs and nmMSCs isolated from 6-8 week old dKO mice were co-cultured in transwell 
chambers. dKO-nmMSCs were plated on the transwell insert and dKO-MDSCs were plated on 
the bottom compartment. After 3-5 days of co-cultures in the presence or absence of neutralizing 
antibodies against sFRP1, dKO-MDSCs were immunostained for fMyHC (Red) and nuclei 
counterstained by Dapi (Blue). Scale bar =50µm. (B) Quantification of the percentage of 
myotubes formed by the dKO-MDSCs of the experiment represented in (A). (n=3). Error bars 
indicate ‘mean ± SD’. *p < 0.005. 
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Figure 20. Enhance Wnt signaling in dKO muscles. 
(A) Representative Western blots of active β-catenin (92kDa) and α-Tubulin (55kDa) in GAS of 
6-8 week old dKO and WT mice. α-Tubulin was used as a loading control. (n=4) (B) β-catenin 
(β-Cat) staining of muscles from 6-8 week old dKO and WT mice (n>4). Scale bar =50µm. (C) 
The average pixel intensity corresponding to β-catenin staining was evaluated with Image J. 
Error bars indicate ‘mean ± SD’. **p < 0.0001. RNA was extracted from frozen muscle tissue 
and real time RT-PCR was performed. Higher (D) Axin2 and (E) LGR5 gene expressions were 
observed from dKO-GAS compared to age-matched WT-GAS (n>4). Error bars indicate ‘mean 
± SD’. **p < 0.0001.   
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4.4 DISCUSSION 
Skeletal muscle possesses the remarkable ability to grow and regenerate itself from both acute 
and chronic damages (10, 61). Despite this, in several pathological conditions, such as Duchenne 
muscular dystrophy (DMD), the skeletal muscle integrity is exacerbated by the infiltration of 
ectopic fat, calcium deposits, and fibrotic tissues (10, 191). In general, declined regeneration and 
accumulation of fat and fibrotic tissue are also associated with the aging process (121). These 
changes in muscle microenvironment could impact stem cell function to delay repair and 
regeneration, and enhance inflammation, which exacerbates the disease condition. Therefore, 
pathological phenotypes of DMD may involve a complex interactions of muscle resident 
stem/progenitor cells with the surrounding microenvironment (93, 125).  
 To better understand effects of muscle milieu on determining stem cell activities, we 
evaluated proliferation and differentiation potentials of non-myogenic mesenchymal stem cells 
(nmMSCs) from skeletal muscles of dystrophic mice (dKO) and cardiotoxin (CTX) injured 
regenerating mice (WT-CTX). Histologic analysis of gastrocnemius muscle (GAS) cryosections 
of dKO mice revealed the expected variations in muscle fiber size, infiltration of mononucleated 
cells, and the presence of adipocytes and fibrotic tissue.  CTX injections for 3 days in WT mice 
resulted in the rapid muscle fiber necrosis and increased number of mononucleated cells within 
the damaged site, leading to the loss of muscle architecture; however, there was no evidence of 
accumulation of lipids or fibrosis as expected.  
Interestingly, the nmMSCs isolated from 6-8 week old dKO and WT-CTX mice 
exhibited similar in vitro and in vivo proliferation and adipogenic/osteogenic potentials. 
Previously, we showed that the nmMSCs isolated from 6-8 week old dKO mice are abnormally 
activated in their proliferation and differentiation capacities compared to that of the WT-
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nmMSCs. Taken these results together, we concluded that the nmMSCs from WT-CTX mice 
were also activated after injury. Further co-cultivation experiments indicated that the nmMSCs 
from regenerating WT-CTX muscles have ability to promote the myogenic potential  of MDSCs, 
whereas the nmMSCs from dystrophic dKO mice significantly inhibit the myogenic potential of 
MDSCs in dKO muscle, which further exacerbates muscular dystrophy. 
Our results are supported by other studies that have reported the presence of muscle 
resident cells/stem cells, which play an important role in supporting SCs to ensure efficient 
muscle repair. Among those cell types is a mesenchymal lineage cell known as fibro/adipogenic 
progenitors (FAPs) whose role in muscle regeneration has been mostly discovered (73, 92). 
Although FAPs do not arise from the myogenic lineage, nor directly participate in forming 
myotubes/myofibers, they have been shown to facilitate muscle regeneration after injury (92). In 
the context of acute muscle injury, muscle damage induces rapid recruitment of pro-
inflammatory immune cells, including eosinophils, which secret IL-4/IL-13 immune signals. The 
activation of IL-4/IL-13 signaling results in activation of FAPs. Activated FAPs can then 
differentiate into the fibroblast lineage while inhibiting their differentiation into adipocytes, to 
create a fibrotic scaffold that supports muscle regeneration (92). In addition, FAPs also generate 
a transient pro-myogenic differentiation niche that facilitates myoblast differentiation (73). A 
more recent study suggests that follistatin is the soluble mediator of functional interactions 
between FAPs and SCs (93). In the context of chronic muscle degenerative disease, such as 
DMD, FAPs undergo extensive proliferation due to unknown factors, and differentiate into 
fibrogenic cells or adipocytes, contributing to accumulation of fatty and fibrotic tissues in 
skeletal muscle (73). In previous study, we also showed that the nmMSCs, which are believed to 
be the similar cell populations to FAPs, in dKO mice showed significantly enhanced adipogenic, 
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osteogenic, and fibrogenic differentiation potentials, suggesting that they may contribute to 
accumulation of non-muscle tissues observed in dKO muscles (191). These studies, including 
ours, provide evidence that FAP/nmMSC phenotype and function are highly influenced by the 
micro-environmental changes occurring in dystrophic muscle.  
In order to decipher the mechanisms behind the inhibitory effects that the nmMSCs 
impart on the myogenic potential of MDSCs, we postulated that the secreted frizzled-related 
protein 1 (sFRP1) might be involved in the process. sFRP1 is known to be an antagonist of  Wnt 
signaling and the constitutive ectopic expression of sFRP1 in preadipocytes disrupts Wnt/β-
catenin signaling, which results in the promotion of adipogenesis in vitro and adipose tissue 
expansion in vivo (140, 193, 194, 196).  Moreover, sFRP1 has also been reported to inhibit the 
myogenesis of satellite cells by down-regulating the expression of myogenin and Mrf4,  both of 
which play roles in myoblast fusion and myofiber maturation (193). We observed higher sFRP1 
mRNA levels in the dKO-nmMSCs compared to age-matched WT-CTX-nmMSCs. ELISA 
results further confirmed that the dKO-nmMSCs were secreting more sFRP1 protein than the 
WT-CTX-nmMSCs, further validating our hypothesis that sFRP1 secreted by the dKO-nmMSCs 
contributes, at least in part, to the micro-environment that inhibits the myogenic differentiation 
of the MDSCs in dKO muscle. Only weak expression of sFRP1 has been reported in WT skeletal 
muscle (194); yet we observed an approximate 8 fold increase in sFRP1 mRNA expression from 
the GAS of 6-8 week old dKO mice compared to age-matched WT-GAS and 4.5 fold increase 
compared to WT-CTX-GAS. These results suggest that sFRP1 may be associated with increased 
proliferation and the adipogenic potential of the nmMSCs isolated from dKO mice. Furthermore, 
it also appears that sFRP1 may play a role in the elevation of adipogenic gene expression and the 
accumulation of lipids observed in the dKO skeletal muscle; however, further studies are 
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required to confirm whether the sFRP1 released by the nmMSCs could contribute to the pro-
adipogenic muscle microenvironment, which promotes fatty infiltration in the skeletal muscle of 
the dKO mice. 
It has been reported that the Wnt signaling is up-regulated in both aged and dystrophic 
mdx skeletal muscle, which consequently leads to an alteration of muscle stem cell 
differentiation  from myogenesis to fibrogenesis (7, 95). Indeed, the up-regulation of 
dephosphorylated β-catenin and increased mRNA expressions of Axin2 and LGR5, well-known 
canonical Wnt signaling target genes (4, 195) suggests that Wnt is also elevated in 6-8 week old 
dKO muscle compared to age-matched WT muscle. This finding was unexpected since sFRP1 is 
a known inhibitor of Wnt signaling pathways. Secreted protein sFRP1 is known to directly bind 
to Wnt molecules to block activation of Wnt/β-catenin signaling pathway (196). Ironically, our 
results indicated that both sFRP1 and Wnt signaling are elevated in dKO skeletal muscles. It may 
be possible that sFRP1 is activated in dKO muscle to antagonize the over-expression of Wnt 
signaling; however, the severe dystrophic muscle micro-milieu in dKO mice may cause the 
dysregulation of sFRP1. As a result, elevated sFRP1 in dKO muscles may involve in promoting 
adipogenesis and fatty degeneration instead of blocking Wnt singling. Further studies required to 
increase our understanding of how sFRP1 interacts with Wnt signaling that promotes the 
differentiation of nmMSCs toward an adipogenic lineage, which may contribute to the severe 
dystrophic phenotype observed in the dKO mice.  
Overall, our data indicated that changes in muscle micro-milieu may affect the stem cell 
activities and behavior of the nmMSCs. We showed that the nmMSCs isolated from WT-CTX 
regenerating muscle produce pro-myogenic signals to MPCs and facilitate myogenic 
differentiation of MPCs, suggesting that they play a crucial role in muscle repair after acute 
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injury. On the other hand, the nmMSCs isolated from fibro-adipogenic dKO skeletal muscle 
significantly impaired the myogenic potential of MPCs, suggesting that the activity of the 
nmMSCs is altered in the chronic disease muscle. We proposed that sFRP1 protein secreted from 
the nmMSCs might be responsible for the inhibitory effect of dKO-nmMSCs on the myogenic 
potential of MPCs. We believe that dysregulation of Wnt signaling in dKO mice is potentially 
involved in the increased sFRP1 protein expression. This may represent one possible mechanism 
behind the up-regulation of sFRP1 in dKO skeletal muscle. However, further studies validating 
our finding and investigating other potential mechanisms are needed. Finally, based on our 
findings, blockade of sFRP1 might be a new therapeutic approach to reduce muscle wasting and 
degeneration in dystrophic muscle.           
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5.0  SUMMARY AND FUTURE DIRECTIONS 
Adult skeletal muscle possesses a remarkable regenerative ability which largely depends on 
muscle progenitor cells such as satellite cells (57). However, in severe muscular dystrophies, 
such as Duchenne muscular dystrophy (DMD), skeletal muscle integrity is debilitated and it is 
often replaced by a mixture of fibrous tissue and white adipocytes in a process termed fibro-
adipogenic degeneration (10, 24, 56, 191). Heterotopic ossification and accumulation of ectopic 
fat and fibrotic tissues in skeletal muscle may alter muscle microenvironment, induce 
stem/progenitor cell dysregulation, and interrupt muscle homeostasis which ultimately lead to 
skeletal muscle weakness. However, current therapies have not found a solution to block or 
replace formation of non-muscle tissues in the DMD skeletal muscle, and the precise origin of 
ectopic adipocytes or fibrotic tissue in dystrophic muscle is also not clearly understood.  
In Chapter 2, based on a previously published preplate technique, we isolated two distinct 
populations of muscle derived cells from skeletal muscles; 1) a rapidly adhering cell population 
(RACs), which is non-myogenic, Pax7- and express the mesenchymal stem cell (MSCs) marker 
PDGFRα, hence we termed this population of cells, non-myogenic MSCs (nmMSCs); and 2) a 
slowly adhering cell population (SACs) which is Pax7+ and highly myogenic, termed muscle 
progenitor cells (MPCs).  Although previously considered as fibroblast-like cells, in this thesis, 
RACs were characterized as mesenchymal lineage stem cells, displaying strong adipogenic, 
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osteogenic, and chondrogenic differentiation potentials and likely involved in the fibrotic and 
fatty infiltration in dystrophic skeletal muscle.  
Previously, we demonstrated that the rapid progression of skeletal muscle wasting and 
degeneration observed in dystrophin/utrophin double knockout (dys-/- utro-/-, dKO) mice is 
closely associated with a rapid depletion of the MPC population pool. (56). In Chapters 3, we 
focused our study on investigating the role of the nmMSCs in skeletal muscle histopathogenesis 
of dKO mice. Accumulation of lipids, calcium deposits, and fibrosis occurred in the skeletal 
muscle of dKO mice as early as 5-7 days of age and histopathologies progressively worsened 
with age. Since MPCs become impaired during the progression of the disease, we hypothesized 
that the nmMSCs may be the primary cells responsible for fibrosis and ectopic adipocytes and 
calcium deposits in DMD. We observed that the nmMSCs isolated from dKO muscle favor 
adipogenesis, osteogenesis, and fibrogenesis more strongly than age-matched wild type (WT) 
counterparts. Moreover, our results indicated that the proliferation and adipogenic/osteogenic 
potentials of the nmMSCs isolated from 1, 4, and 6-8 week old dKO mice were progressively 
activated during the course of the disease, suggesting that the activation of the nmMSCs is 
closely associated with the deposition of non-muscle tissues in the skeletal muscle of dKO mice.  
Fat accumulation/infiltration is also a commonly recognized consequence of massive 
rotator cuff tears (RCTs), which is a tear of one or more of the tendons of the four rotator cuff 
muscles of the shoulder (197, 198). RCTs are among the most common injuries seen by 
orthopaedic surgeons and massive RCTs have been found to be associated with atrophy, fibrosis, 
and fat accumulation/infiltration (197). Clinically, these pathologic changes have been shown to 
be irreversible and have been correlated with poor prognosis and functional outcomes; however, 
the pathophysiology behind fat accumulation is still not clear (199).  It has been suggested that 
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loss of mechanical stretch in muscles could trigger adipogenic lineage differentiation in MSCs or 
precursor cells within the muscle, possibly leading to the fatty degeneration observed in massive 
RCTs (197). Interestingly, one previous study proposed that mechanical stretch of muscles, 
which occurs during normal activity, activates the classical NF-κB pathways in mdx mice and 
this pathway could be predominately active in DMD since dystrophin deficiency in ndx mice 
causes skeletal muscles to be more susceptible to mechanical stretch or injury (200). These 
studies suggest that persistent stimulation of skeletal muscle fibers by mechanical forces or stress 
may regulate adipogenic potential of nmMSCs or other muscle resident progenitors and result in 
the development of muscular dystrophy. Future studies investigating effects of mechanical 
stretch on proliferation or differentiation potentials of nmMSCs will facilitate development of a 
novel therapy to prevent the progression of fat accumulation and enhance muscle regeneration in 
patients with DMD and massive RCTs.  
Aside from contributing to formation of ectopic non-muscles tissues in dystrophic 
muscle, the nmMSCs may be a potential source of inhibitory muscle regeneration signaling that 
occurs during the chronic disease progression of DMD. As discussed in Chapter 3, the nmMSCs 
isolated from 6-8 week old dKO mice severely inhibit the myogenic differentiation of dKO-
MPCs through the down-regulating genes that are important for myoblast maturation and 
terminal myogenic differentiation. Taken all together, our data indicated that the activation of the 
nmMSCs in dKO muscles may escalate the disease process by depositing fat, calcium aggregates, 
and fibrotic tissues in skeletal muscle as well as impair muscle regeneration through inhibition of 
the myogenic potential of MPCs. We further investigated soluble factor(s) secreted from the 
dKO-nmMSCs that limit the myogenic potentials of MPCs in the later chapter.  
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Experiments done in Chapter 4 suggest that the inhibitory effect of the nmMSCs on the 
myogenic potential of MPC was mediated by the secretion of secreted frizzled-related protein 1 
(sFRP1). In fact, blockade of soluble sFRP1 secreted from dKO-nmMSCs using neutralized 
antibodies significantly improved myotube formation by MPCs co-cultivated with dKO-
nmMSCs, supporting our hypothesis that sFRP1 is likely the secreting factor that inhibit the 
myogenic potential of MPCs.   
Finally, we also examined the role of the nmMSCs in skeletal muscle regeneration.  The 
purpose of this study was to determine how muscle microenvironment affects the activities and 
function of the nmMSC. In contrast to fibro-adipogenic environment in dKO skeletal muscle, 
WT-CTX muscle rarely induces adipocyte or fibrosis accumulation in the skeletal muscle. 
Therefore, we hypothesized that the behavior of the nmMSCs in WT-CTX-GAS is regulated in a 
manner distinct to those in dKO skeletal muscle. Interestingly, our results indicated that the 
nmMSCs were activated after acute muscle injury to facilitate MPC myogenesis via paracrine 
mechanism. We observed significantly higher level of myotube formation from MPCs co-
cultured with the nmMSCs isolated from cardiotoxin injured regenerating muscle compared to 
MPCs alone. Our finding is supported by other investigations suggesting that the nmMSCs are in 
fact a crucial cellular compartment necessary for successful muscle repair and tissue homeostasis 
in WT muscle (44, 73, 92). The precise pro-myogenic signals/factors released from the nmMSCs 
during muscle repair process remain unidentified although interleukin-6 and follistatin are under 
investigation as candidates (73, 93). Our results suggest that the supporting effect of the 
nmMSCs in WT skeletal muscle regeneration through activation of MPCs is completely altered 
in the dKO skeletal muscle, an effect likely related to the fibro-adipogenic micro milieu in the 
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dKO skeletal muscle. This finding confirms our hypothesis that changes in muscle 
microenvironment induce abnormal alterations in stem cell activities.     
In conclusion, based on our results and summarized in Figure 21, we propose that the 
nmMSCs represent a major contributor to the formation of ectopic fat, calcification, and fibrosis 
in the skeletal muscle of dKO mice, and that the activation of the nmMSCs may exacerbate the 
regeneration of the dystrophic muscle by inhibiting the myogenic potential of MPCs. More 
interestingly, in regenerating skeletal muscle of WT mice, the nmMSCs potentially support 
muscle regeneration of MPCs and are required for successful muscle repair, suggesting that in 
disease setting, these cells adopt a different fate leading to the development of fibrosis and fatty 
infiltration. It has been reported that MPCs from dKO mice are rapidly depleted, contributing to 
continuous muscle wasting and degeneration (201). Studies done in this dissertation reveal that 
while MPCs are depleted, the nmMSCs are activated and worsen the disease progression by 
forming ectopic non-muscle tissues and impairing muscle regeneration. Overall, data from this 
dissertation propose that a therapeutic strategy targeting activated nmMSCs could be a potential 
treatment for DMD.   
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Figure 21. A schematic represents the role of the nmMSCs in skeletal muscle of dKO mice. 
 
Our results agree with several other studies reporting presence of mesenchymal lineage 
progenitor cells, named PDGFRα+ cells, FAPs, and Tie2+ cells, in the skeletal muscle, whose 
activation in disease model or chemically induced fatty degenerating mouse resulted in formation 
of ectopic bone or adipose/fibrotic tissues (73, 94, 106). PDGFRα is the common cell surface 
maker shared by all of the above cell types and therefore, preventing the activation of PDGFRα 
expressing cells in skeletal muscle may be a promising therapy to improve muscle wasting and 
fibro-adipogenic degeneration in DMD. Most recently, Ito et al. reported that imatinib mesylate, 
which inhibits signaling of tyrosine kinase receptors, including PDGFRα, attenuates muscle 
necrosis, calcium accumulation, and fibrosis in mdx mice. Their study showed imatinib treatment 
in mdx mice inhibited proliferation and fibrosis-gene expression in muscle PDGFRα+ cells, 
without affecting myoblasts. However, they observed several unexpected side effects of imatinib, 
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including heart problem, no effect on fibrosis of diaphragm, and impaired muscle regeneration. 
In addition, the role of imatinib on other type of cells, such as infiltrating mononuclear cells, in 
the skeletal muscle is unclear (202). DMD is a genetic disorder that requires a long-term 
treatment to prevent any pathological changes. A study done by Ito et al. suggests that more-
specific PDGFRα inhibitors are required.  
Our data demonstrated that targeting sFRP1 might be a better therapeutic approach for 
treating DMD. sFRP1 has reported to inhibit C2C12 cell myogenic differentiation (193), but it is 
also a well-known inhibitor of Wnt signaling pathway whose action leads to activation of 
adipogenic genes and adipogenesis (143, 194). Results from Chapter 4 indicated that sFRP1 gene 
expression was elevated in dKO skeletal muscle and the dKO-nmMSCs secreted higher sFRP1 
protein compared to WT controls. Therefore, we proposed that not only does the sFRP1 released 
by the nmMSCs hinder muscle regeneration, but it also contributes to establishing a pro-
adipogenic muscle microenvironment, which promotes fibro-adipogenic degeneration in the 
skeletal muscles of the dKO mice. This finding strongly urged us to investigate whether the 
blockade of sFRP1 in dKO muscle would reduce fat/fibrotic tissue accumulation and delay 
muscle degeneration, ultimately improving muscle function and extending life and health span. 
Furthermore, for more general applications of sFRP1 in other types of muscle disease, better 
understanding of how and why sFRP1 expression was upregulated in dKO muscles is needed.  
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